 
 Clinical Trial Protocol : THR-1442 -C-423 
Study Title:  A Phase 3, Randomized, Double -Blind, Active -Controlled Study  to 
Evaluate the Effects of Bexagliflozin versus Sitagliptin in Subjects 
with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic 
Control by Metformin  
Study Number:  THR -1442 -C-423 
Study Phase:  3 
Product Name:  Bexagliflozin Tablets  
Indication:  Type 2 Diabetes Mellitus  
Investigators:  Multicenter  study  
EudraCT Number:  2017 -000420 -95 
IND Number:  103822  
Sponsor:  Theracos Sub, L LC 
Sponsor Contact:  Lynelle Cortellini, MSc  
Translational Medicine Group  
Massachusetts General Hospital  
185 Cambridge Street, Boston, MA 02114  
Phone:  617 -724-8420  
Fax:  617 -643-8203  
E-mail: lcortellini@ccib.mgh.harvard.edu   
Medical Monitor:  Robert Klugman M.D.  
Theracos Sub, LLC  
225 Cedar Hi ll Road, Suite 200, Marlborough, MA 01752  
Phone: 508 -735-9491  
Fax: 617 -643-8203  
Email: rklugman@theracos.com  
 
 Date  
Protocol Version 2.0 06 April 2017  
 
Confidentiality Statement  
The information in this documen t is the confidential information of Theracos Sub, LLC 
(“Theracos”) and must not be disclosed, used, or copied except with prior written approval 
from Theracos or to the extent required by applicable laws, rules and regulations . 
 
  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 2 of 69 Global Versio n 2.0 TABLE OF CONTENTS  
SYNOPSIS  ................................ ................................ ................................ ................................ .7 
LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  ................................ .......... 12 
1 INTRODUCTION  ................................ ................................ ................................ ........... 14 
1.1 Type 2 Diabetes Mellitus  ................................ ................................ ....................... 14 
1.2 Bexagliflozin for the Treatment of Type 2 Diabetes Mellitus  ............................... 15 
2 STUDY OBJECTIVES  ................................ ................................ ................................ ....16 
2.1 Primary Objective  ................................ ................................ ................................ ..16 
2.2 Key Secondary Objectives  ................................ ................................ ..................... 16 
2.3 Exploratory Objectives  ................................ ................................ .......................... 16 
3 INVESTIGATIONAL PLAN  ................................ ................................ .......................... 17 
3.1 Overall Study Design and Plan  ................................ ................................ .............. 17 
3.2 Research Method s and Procedures  ................................ ................................ ........ 17 
3.2.1  Run-in Period  ................................ ................................ ............................... 17 
3.2.2  Treatment Period  ................................ ................................ .......................... 18 
3.2.3  Glycemic Control Monitoring ................................ ................................ ......19 
3.2.3.1  Placebo Run -in Period  ................................ ................................ .......19 
3.2.3.2  Treatment Period  ................................ ................................ ................ 19 
3.2.3.3  Rescue Medication  ................................ ................................ ............. 19 
3.2.4  Other Safety Monitoring Activities  ................................ ............................. 20 
3.2.5  Data an d Safety Monitoring Board (DSMB)  ................................ ............... 21 
3.2.6  Major Adverse Cardiovascular Event (MACE) Adjudication  ..................... 21 
3.2.7  Diabetic Ketoacidosis (DKA) Event Adjudication  ................................ ......21 
3.3 Rational for Study Design and Procedures  ................................ ............................ 22 
3.3.1  Rationale for the Study Design  ................................ ................................ ....22 
3.3.2  Rationale for Background Medication and Active Comparator  .................. 22 
3.3.3  Rationale for the Dose Selection ................................ ................................ ..23 
3.4 Study Duration and Dates  ................................ ................................ ...................... 23 
4 STUDY POPULATION SEL ECTION  ................................ ................................ ........... 24 
4.1 Study Population  ................................ ................................ ................................ ....24 
4.2 Inclusion Criteria  ................................ ................................ ................................ ...24 
4.3 Exclusion Criteria  ................................ ................................ ................................ ..24 
5 STUDY TREATMENTS  ................................ ................................ ................................ .26 
5.1 Description of Treatments ................................ ................................ ...................... 26 
5.1.1  Investigational Product  ................................ ................................ ................ 26 
5.1.2  Active Comparator  ................................ ................................ ....................... 26 
5.2 Treatments Administered  ................................ ................................ ....................... 26 
5.2.1  Investigational Pro duct ................................ ................................ ................ 26 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 3 of 69 Global Versio n 2.0 5.2.2  Active Comparator  ................................ ................................ ....................... 26 
5.2.3  Background Metformin Therapy  ................................ ................................ .27 
5.3 Selection and Timing of Dose for Each Patient  ................................ ..................... 27 
5.3.1 Bexagliflozin  ................................ ................................ ................................ 27 
5.3.2  Sitagliptin  ................................ ................................ ................................ .....27 
5.4 Method of Assigning Treatment Groups and Study Drugs  ................................ ...27 
5.5 Blinding ................................ ................................ ................................ .................. 28 
5.6 Concomitant Therapy ................................ ................................ ............................. 28 
5.6.1  Diuretics and Medications for Treatment of Dyslipidemia and 
Hypertension  ................................ ................................ ................................ 29 
5.7 Restrictions  ................................ ................................ ................................ ............ 29 
5.7.1  Prior Therapy  ................................ ................................ ............................... 29 
5.7.2  Fluid and Food Intake  ................................ ................................ .................. 29 
5.7.3  Subject Activity Re strictions  ................................ ................................ .......30 
5.8 Treatment Compliance  ................................ ................................ ........................... 30 
5.9 Packaging and Labeling  ................................ ................................ ......................... 30 
5.9.1  Run-in Kits  ................................ ................................ ................................ ...30 
5.9.2  Bexagliflozin Kit  ................................ ................................ .......................... 30 
5.9.3  Sitagliptin Kit  ................................ ................................ ............................... 31 
5.10  Storage and Accountability  ................................ ................................ .................... 31 
5.11  Investigational Product Retention at Study Site  ................................ .................... 31 
6 STUDY PROCEDURES  ................................ ................................ ................................ .32 
6.1 Informed Consent ................................ ................................ ................................ ...32 
6.2 Screening for I/E Criteria  ................................ ................................ ....................... 32 
6.3 Medical History  ................................ ................................ ................................ .....32 
6.3.1  General Demographics and Characteristics  ................................ ................. 32 
6.3.2  Diabetes History ................................ ................................ ........................... 33 
6.3.3  Cardiovascular Disease History  ................................ ................................ ...33 
6.3.4  Medication History  ................................ ................................ ...................... 33 
6.4 Diet and Exercise Counseling  ................................ ................................ ................ 33 
6.5 Physical Examination ................................ ................................ ............................. 33 
6.6 Abbreviated Physical Examination  ................................ ................................ ........ 33 
6.7 Body Weight  ................................ ................................ ................................ .......... 34 
6.8 Vital Signs  ................................ ................................ ................................ .............. 34 
6.9 Electrocardiography  ................................ ................................ ............................... 34 
6.10  Clinical Laboratory Test s ................................ ................................ ....................... 35 
6.10.1  Laboratory Parameters  ................................ ................................ ................. 35 
6.10.2  Sample Collection, Storage, and Shipping  ................................ .................. 35 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 4 of 69 Global Versio n 2.0 6.10.3  Urinalysis  ................................ ................................ ................................ .....35 
6.11  Laboratory Tests  ................................ ................................ ................................ ....37 
6.12  Diary and Glucometer Dispensation  ................................ ................................ ......38 
6.13  Dispensing Run -in Drug  ................................ ................................ ........................ 38 
6.14  Diary and Glucometer Record Review  ................................ ................................ ..38 
6.15  Dispensing Investigational Product  ................................ ................................ .......38 
6.15.1  Drug A ccountability ................................ ................................ ..................... 38 
6.16  Adverse Events Assessments  ................................ ................................ ................. 39 
6.16.1  Definition of Adverse Events ................................ ................................ .......39 
6.16.2  Eliciting and Reporting AEs  ................................ ................................ ........ 40 
6.16.3  Immediately Reportable AEs  ................................ ................................ .......41 
6.16.4  Pregnancy  ................................ ................................ ................................ .....41 
6.16.5  Procedure for Breaking the Blind  ................................ ................................ 42 
6.16.6  Follow -up of Non -Serious AEs  ................................ ................................ ...42 
6.16.7  Follow -up of Post -Study SAEs  ................................ ................................ ....42 
6.16.8  Urinary Tr act Infections (UTIs)  ................................ ................................ ...43 
6.16.9  Genital Mycotic Infections (GMIs)  ................................ ............................. 43 
6.16.10  Hepatotoxicity  ................................ ................................ .............................. 43 
6.16.11  Hypoglycemia  ................................ ................................ .............................. 44 
6.16.12  Major Adverse Cardiovascular Event (MACE)  ................................ ........... 46 
6.16.13  Diabetic Ketoacidosis (DKA)  ................................ ................................ ......47 
6.16.14  Amputation  ................................ ................................ ................................ ..47 
6.16.15  Pancreatitis  ................................ ................................ ................................ ...47 
6.17  Concomitant Medication Assessments  ................................ ................................ ..48 
7 STUDY ACTIV ITIES  ................................ ................................ ................................ .....49 
7.1 V1/ Screening ................................ ................................ ................................ ......... 49 
7.2 V2/ Run In ................................ ................................ ................................ .............. 49 
7.3 V3/ Randomization  ................................ ................................ ................................ 49 
7.4 V4/ 6 weeks ................................ ................................ ................................ ............ 50 
7.5 V5/ 12 weeks ................................ ................................ ................................ .......... 50 
7.6 V6/ 18 weeks ................................ ................................ ................................ .......... 50 
7.7 V7/ End of Treatment  ................................ ................................ ............................ 50 
7.8 V8/ Follow up  ................................ ................................ ................................ ........ 51 
7.9 Early Termination Procedures  ................................ ................................ ............... 51 
8 QUALITY CONTROL AND ASSURANCE  ................................ ................................ .52 
9 PLANNED STATISTICAL METHODS  ................................ ................................ ........ 53 
9.1 General Considerations  ................................ ................................ .......................... 53 
9.2 Determination of Sample  Size ................................ ................................ ............... 53 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 5 of 69 Global Versio n 2.0 9.3 Analysis Populations  ................................ ................................ .............................. 54 
9.3.1  Intention -to-Treat Analysis Set  ................................ ................................ ....54 
9.3.2  Safety Analysis Set  ................................ ................................ ...................... 54 
9.3.3  Per Protocol Analysis  Set................................ ................................ ............. 54 
9.4 Demographics and Baseline Characteristics  ................................ .......................... 54 
9.4.1  Concomitant Medications  ................................ ................................ ............ 55 
9.5 Primary Efficacy Analyses  ................................ ................................ .................... 55 
9.5.1  Hypotheses for the Primary Endpoint  ................................ .......................... 55 
9.5.2  Statistical Methods for Primary Analyses ................................ .................... 55 
9.5.3  Analysis of Dropouts Pattern  ................................ ................................ .......56 
9.6 Secondary Efficacy Analyses  ................................ ................................ ................ 56 
9.7 Other Efficacy Analyses  ................................ ................................ ........................ 56 
9.8 Analysis of Safety  ................................ ................................ ................................ ..57 
9.8.1  Adverse Events  ................................ ................................ ............................ 57 
9.8.2  Adverse Events of Interest  ................................ ................................ ........... 57 
9.8.3  Clinical and Laboratory Events and Analyses  ................................ ............. 58 
9.8.4  Physical Examination ................................ ................................ ................... 58 
9.9 Interim Analysis  ................................ ................................ ................................ .....58 
9.10  Final Analysis  ................................ ................................ ................................ ........ 58 
10 ADMINISTRATIVE CONSI DERATIONS  ................................ ................................ ....59 
10.1  Investigators and Study Administrative Structure  ................................ ................. 59 
10.2  Institutional Review Board (IRB) or Independent Ethics Committee (IEC) 
Approval  ................................ ................................ ................................ ................ 59 
10.3  Ethical Conduct of the Study  ................................ ................................ ................. 59 
10.4  Subject Information and Consent ................................ ................................ ........... 60 
10.5  Subject Confidentiality  ................................ ................................ .......................... 60 
10.6  Study Monitoring  ................................ ................................ ................................ ...61 
10.7  Case Report Forms and Study Records  ................................ ................................ .61 
10.8  Data Monitoring Committee  ................................ ................................ .................. 61 
10.9  Protocol Violations/Deviations  ................................ ................................ .............. 61 
10.10  Access to Source Documentation  ................................ ................................ .......... 62 
10.11  Retention of Data  ................................ ................................ ................................ ...62 
10.12  Publication and Disclosure Policy  ................................ ................................ ......... 63 
11 REFERENCE LIST  ................................ ................................ ................................ ......... 64 
 
LIST OF IN -TEXT TABLES  
Table  1. Treatment Groups and Assigned Treatment  ................................ ................ 18 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 6 of 69 Global Versio n 2.0 Table 2 List of Laboratory Tests  ................................ ................................ ............... 37 
 
LIST OF APPENDICES  
Appendix 1  Schedule of Events  ................................ ................................ ............. 65 
Appendix 2  Schedule of Clinical Laboratory Tests  ................................ ............... 66 
Appendix 3  Examples of SGLT2 Inhibitors  ................................ .......................... 67 
Appendix 4  Sponsor Signatures ................................ ................................ ............. 68 
Appendix 5  Investigator’s Signature  ................................ ................................ .....69 
 
 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 7 of 69 Global Versio n 2.0 SYNOPSIS  
Sponsor : Theracos Sub, L LC 
Name of Finished Product:  Bexagliflozin Tablets   
Name of Active Ingredient:  Bexagliflozin   
Study  Title : 
A Phase 3, Randomized, Double -Blind, Active -Controlled Study  to Evaluate the Effects of 
Bexagliflozin versus Sitagliptin in Subjects with Type 2 Diabetes Mellitus Who Have 
Inadequate Glycemic Control by Metformin   
Study Number:  THR -1442 -C-423 
Study Phase:  3 
Primary Objective:   
The primary efficacy objective  is to demonstrate that bexagliflozin is non -inferior to 
sitagliptin  by evaluating  the treatment effect  on hemoglobin A1c ( HbA1c ) reduction  at week 
24 in subjects whose type 2 diabetes mellitus  (T2DM)  is inadequately controlled by 
metformin.  
Secondary Objective s: 
The key secondary objectives are : 
• To evaluate the treatment ef fect of bexagliflozin vs. sitagliptin on the change in fasting 
plasma glucose (FPG) at week 24  
• To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in body 
weight in subjects with baseline body mass in dex (BMI) ≥  25 kg/m2 at week  24 
• To evaluate the treatment effect of bexagliflozin vs. sitagliptin on the change in systolic 
blood pressure (SBP) in subjects at week 24 
Exploratory  Objectives :  
• To assess the treatment effect of bexagliflozin vs. sitagliptin on the change in the 
propor tion of subjects achieving HbA1c  < 7.0% over time  
• To assess the treatment effect of bexagliflozin vs. sitagliptin on the change in HbA1c 
over time  
• To assess the treatment effect of bexagliflozin vs. sitagliptin on the change in fasting 
plasma glucose (FPG)  over time  
• To assess the treatment effect of bexagliflozin vs. sitagliptin on the change in body 
weight over time   
• To assess the treatment effect of bexagliflozin vs. sitagliptin on the change in SBP over 
time 
Safety Objectives:  
• To compare the effects of bexagliflozin with sitagliptin  on the incidence of adverse 
events  (AE)  of interest. AE of interest are urinary tract infections , urosepsis and 
pyelonephritis, genital mycotic infections  (GMI) , diuretic effects including hypovolemia, 
hypotension episodes, h ypoglycemia, hepatotoxicity, major adverse cardiovascular events 
(MACE), falls and fractures, malignancies, hypersensitivity reactions, acid -base disorders 
including diabetic ketoacidosis (DKA) , pancreatitis, amputations, and renal failure events  
• To compare  the effects of bexagliflozin with sitagliptin  on general safety assessments 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 8 of 69 Global Versio n 2.0 including treatment emergent AEs, clinical laboratory findings , 12-lead 
electrocardiograms (ECG) parameters, physical examinations, vital signs including 
orthostatic blood pressur e (BP), and use of concomitant medications . 
Study Design :  
THR -1442 -C-423 is a phase 3, multi -center, randomized, double -blind, active controlled  
study to evaluate the efficacy and safety of bexagliflozin  versus sitagliptin  in subjects  whose  
T2DM is not w ell controlled by metformin  alone . A total of  374 subjects  are planned to be 
randomized in a ratio of 1:1 to receive once daily treatment of bexagliflozin  tablets, 20 mg,  
with sitagliptin  tablets, placebo  (Group 1) or bexagliflozin  tablets, placebo,  with sitagliptin  
tablets, 100 mg  (Group 2) for 24 weeks  in an outpatient setting.  
The m ain eligibility criteria include 1) male or female subjects with T2DM  and 2) screening 
HbA1c between 7 .0% and 11% (inclusive) .  
Qualified  subjects must have taken metformin at a stable dose of  ≥ 1500  mg/day  in addition 
to diet and exercise counseling  for at least  8 weeks prior to screening. Study subjects will 
continue taking open -labeled metformin during the entire study.  
All eligible subjects will start a single -blind run-in period  by taking  placebo bexagliflozin 
and placebo sitagliptin  once daily for one week . Subjects who meet all inclusion criteria and 
no exclusion criteria after completion of the run -in period will be eligible for randomization 
and receive investigational product s.  
During the treatment period, subjects will receive  once daily  sitagliptin  tablets , 100 mg, and 
bexagliflozin  tablets , placebo , or bexagliflozin  tablets , 20 mg, and sitagliptin  tablets , placebo , 
for 24 weeks . Each subject will be instructed to return to the cl inic at weeks  6, 12, 18, and 24 
for efficacy as sessment and safety monitoring. Subjects will return to the clinic for a follow -
up exit visit at week 26 or 2 week s after last dose of study drug  if subject s early terminate  
prior to week 24. 
During the study , a D ata and Safety Monitoring Board (DSMB) will review the unblinded 
data periodically and may recommend an early termination of the trial for safety reasons. In 
the event of administrat ive changes  or other  related  reasons, the sponsor reserves the right to 
terminate the study early. There will be no  interim analysis ; final statistical analys is will be 
performed after all subjects complete the study . 
Study Population  and Main Eligibility Criteria :  
A total of 374 eligible subjects  are planned for this study. The study population will 
comprise:  
1. Male or female adult subjects ≥ 18 years of age   
2. If subjects are female of childbearing potential , subjects  must be negative on the urine 
pregnancy test and agree to abstain from coitus or use contraception  during the entire 
study to avoid any possible pregnanc y 
3. Subjects with a diagnos is of T2DM with HbA1c levels between 7.0% and 11% 
(inclusive) at screening  
4. Subjects whose T2DM is treated with a stable dose of ≥ 1500  mg/day metformin  only 
along with diet and exercise counseling for at least 8 weeks prior to screening  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 9 of 69 Global Versio n 2.0 5. Subjects with a BMI ≤ 45 kg/m2 at screening  
6. If applicable, taking stable doses of treatment for dyslipidemia and/or hypertension for 30 
days prior to screening. Subjects do not need to be treated for dyslipidemia or 
hypertension to be eligible for the  study  
7. Subjects who are  willing and able to return for all clinic visits and to complete all study -
required procedures, including self -monitor ing blood glucose (SMBG) measurement s 
 
Prior to randomization, all subjects must : 
8. Adhere  to the investigational product administration re quirements as evidenced by 
missing no more than 1 day of  placebo run -in medication  
Test Product s, Dose , and Mode of Administration:  
Once daily oral administration of bexagliflozin and sitagliptin  with or without food taken 
together in the morning  
• Group 1: bexagliflozin tablets , 20 mg, and sitagliptin  tablets , placebo   
• Group 2:  bexaglifl ozin tablets , placebo, and  sitagliptin  tablets , 100 mg 
Duration of Treatment :  
Eligible subjects  will receive a total treatment duration of  25 weeks including 1 week  of run-
in medication s and 24 weeks of investigational product s. 
Efficacy  Assessments : 
Primary efficacy assessment : 
• Change in HbA1c from baseline  at week 24 
Secondary efficacy assessment s: 
• Change in FPG from baseline at week 24  
• Change in body weight in subject s with baseline BMI  ≥ 25 kg/m2 at week 24 
• Change in SBP  in subjects from baseline at week 24 
Other efficacy endpoints:  
• To assess the treatment effect of bexagliflozin vs. sitagliptin on the change in the 
proportion of subjects achieving HbA1c <  7.0% over t ime 
• To assess the treatment effect of bexagliflozin vs. sitagliptin on the change in HbA1c 
over time  
• To assess the treatment effect of bexagliflozin vs. sitagliptin on the change in (FPG over 
time  
• To assess the treatment effect of bexagliflozin vs. sitagl iptin on the change in body 
weight over time   
• To assess the treatment effect of bexagliflozin vs. sitagliptin on the change in SBP over 
time 
Safety Endpoints:  
• Treatment emergent AEs, including AEs of special interest  (genital and urinary tract 
infections, diuretic effects, hepatotoxicity, MACE, hypoglycemia, fractures, malignancy, 
hypersensitivity reactions, hypotensive episodes, acid -base disorders, pancreatitis, 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 10 of 69 Global Versio n 2.0 amputations and renal failure events)  
• Laboratory testing , including hematology, serum chemistr y, and urinalysis  
• Physical examination  
• 12-lead ECG  
• Vital signs  
• Concomitant medication use  
Statistical Methods:   
The primary hypothesis is that bexagliflozin is non -inferior to sitagliptin  by evaluating the 
treatment effect  on HbA1c reduction at week 24 in combination with metformin . The non -
inferiority margin for mean change from  baseline at week  24 in HbA1c comparing 
bexagliflozin group with sitagliptin  group will be 0.35%. Superiority will be declared without 
additional statistical testing when the upper  bound of the 95% CI for difference in change 
from baseline at week  24 in HbA1c comparing bexagliflozin group with sitagliptin  group is 
less than 0. The treatment difference will be examined by using a mixed model repeated 
measures (MMRM) analysis of covar iance model (ANCOVA). The model will include  
treatment, visit, treatment -by-visit interaction , region and the baseline HbA1c value as a 
fixed effect covariate. Least squares mean treatment differences between the bexagliflozin 
group and the comparator grou p at week 24  in change  from baseline will be estimated from 
the model. An unstructured covariance will be used to model the within -subject correlation. 
If the model with the unstructured covariance structure does not converge, an autoregressive  
(1) covaria nce structure will be used.  HbA1c values obtained after the start of rescue 
medication will  not be excluded from this primary analysis.  Primary endpoint s will be 
analyzed on both intention -to-treat ( ITT) and per protocol ( PP) analysis sets.  
The MMRM model is one approach to obtain treatment effect estimates in the presence of 
missing data. As sensitivity analyses for missing data, the following will be performed  on 
both ITT and PP analysis sets : 
1. Missing data will be imputed via multiple imputations , followi ng which the MMRM will 
be repeated on the complete datasets with results combined across com plete datasets 
using standard multiple imputation  techniques; HbA1c values collected after the start of 
rescue medication will be excluded . 
2. Missing data will be imp uted via last observation carried forward  (LOCF ), following 
which the MMRM will be repeated; HbA1c values collected after the start of rescue 
medication will be considered missing.  
3. HbA1c values collected after the start of rescue medication will be conside red missing, 
and the MMRM analyses will be re -performed.  
 
The effect s of bexagliflozin  on the changes  from baseline  at week 24  in FPG, body weight 
and SBP  will be tested as  key secondary endpoints and will be analyzed in a hierarchical 
testing strategy an d only if the primary objective is met . Similar to the primary endpoint, 
MMRM ANCOVA models will be used . A hierarchical testing strategy will be followed to 
preserve experiment -wide alpha at 0.05:  
1. Superiority test of the change in FPG in the bexagliflozin  group vs. the sitagliptin group 
at week 24  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 11 of 69 Global Versio n 2.0 2. Superiority  test of the change in body weight in subjects with baseline BMI ≥ 25 kg/m2 in 
the bexagliflozin group vs. the   sitagliptin  group  at week 24  
3. Superiority test of the change in SBP in the bexagliflozin g roup vs. the  sitagliptin  group  
at week 24  
 
Additional effects of bexagliflozin  versus sitagliptin  on the chang es in HbA1c, FPG, SBP, 
body weight , and the proportion of su bjects who reach an HbA1c  < 7%, as well as the 
general safety in subjects with T2DM , will be analyzed  as exploratory efficacy  endpoints. 
These endpoints are considered exploratory and will not be adjusted for multiplicity.  
For the primary efficacy endpoint , a minimum of 1 72 subjects are needed in each treatment 
arm to detect non -inferiority  of bexagliflozin to sitagliptin  with respect to the change in 
HbA1c from baseline at week 24  by a margin of 0.35%, assuming an estimated pooled 
standard deviation  (SD)  of 1.0 %. This estimation is based on a one-sided t -test with 90 % 
power at a 0.025  level  of significance. To allow for an estimated 8.0% dropout rate, 187 
patients will be randomized in each treatment arm , and the total sample size will be 374 
subjects for this study .  
Statistical analyses and summaries will be performed using SAS® software ( SAS Institute, 
Cary, NC) .  
Date of Protocol  V2.0: 06 April 2017  
Date of Protocol V1.0: 01 February 2017  
 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 12 of 69 Global Versio n 2.0 LIST OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
ADA  American Diabetes Association  
AE adverse event  
ALB  albumin  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
ANCOVA  analysis of covariance  
AST  aspartate aminotransferase  
ATC  Anatomic Therapeutic Chemical classification  
BMI  body mass index  
BP blood pressure  
BUN  blood urea nitrogen  
CEC  cardiovascular endpoint c ommittee  
CI confidence interval  
CRF  case report form 
CRO  contract research organization  
DKA  diabetic ketoacidosis  
DPP4  dipeptidyl peptidase -4 
DSMB  Data and Safety Monitoring Board  
ECG  electrocardiogram  
eGFR  estimating glomer ular filtration rate  
FPG fasting plasma glucose  
GCP  Good Clinical Practice  
GLP -1 glucagon -like peptide -1 
GMI  genital mycotic infection  
h hour 
HbA1c  hemoglobin A1c  
Hct hematocrit  
HDL -C high-density lipoprotein cholesterol  
HDPE  high-density polyethy lene 
Hgb hemoglobin  
HUA  hospitalization for unstable angina  
ICH International Conference for Harmonisation  
IEC  Independent Ethics Committee  
IRAE  immediately reportable adverse event 
IRB Institutional Review bBoard 
ITT intention -to-treat 
IWRS  Interactive Web Response System  
LDL -C low density lipoprotein cholesterol  
LOCF  last observation carried forward  
MACE  major adverse cardiovascular event 
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 13 of 69 Global Versio n 2.0 MCV  mean corpuscular v olume  
MDRD  modification of diet in renal disease  
MedDRA  medical dictionary for regulatory activities  
MI myocardial infarction  
MMRM  mixed model repeated measures  
MODY  maturity –onset diabetes of the young  
N number of subjects  
OHA  oral hypoglycemic age nt 
PP per protocol  
PR time from the beginning of the P wave to the beginning of the QRS complex in 
electrocardiogram  
QRS  QRS complex the combination of three of the graphical deflections seen on a typical 
electrocardiogram  
QT a measure of the time betw een the start of the Q wave and the end of the T wave in the 
heart's electrical cycle  
RBC  red blood cell (count)  
SAE  serious adverse event  
SBP systolic blood pressure  
SD standard deviation  
SGLT2  sodium glucose cotransporter 2  
SMBG  self-monitored  blood glucose  
SOP standard operating procedure  
SU sulfonylurea  
SUSAR  serious and unexpected suspected adverse event  
TIA transient ischemic attack  
T2DM  type 2 diabetes mellitus  
TC total cholesterol  
TEAE  treatment emergent adverse event  
TG triglycerides  
TZD  thiazolidinedione  
UACR  urine albumin to creatinine ratio  
UADR  unexpected adverse drug reaction  
UGE  urinary glucose excretion  
ULN  upper limit of normal  
UPT  urinary pregnancy test  
UTI urinary tract infection  
WBC  white blood cell (count)  
WHO -DD World Health Organization Drug Dictionary  
WOCBP  women of childbearing potential  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 14 of 69 Global Versio n 2.0 1 INTRODUCTION  
Type 2 diabetes mellitus (T2DM) is one of the leading causes of morbidity and mortality 
worldwide, affecting an estimated 415 million people in 2015 . Approximatel y 187 million of 
those affected are thought to be unaware of their condition and over 80% reside in low - and 
middle -income countries  (IDF 2015 ). 
1.1 Type 2 Diabetes Mellitu s 
T2DM is the predominant form of diabetes and accounts for at least 90% of all diabetes 
cases, which is characterized by insulin resistance and relative or absolute insulin 
insufficiency. Despite the availability of several classes of therapeutics, the nu mber of people 
with diabetes is projected to increase by nearly 55% to over 642 million adults by 2040 (IDF 
2015 ). Among the debilitating consequences of T2DM are perip heral neuropathy, 
retinopathy, renal failure, peripheral ischemia and exacerbations of cardiovascular disease, 
which result in blindness, amputation, dialysis , and death.  
T2DM is a disease strongly linked to increased body fat mass in the majority of cases  
(Schwartz, Fabricatore et al. 2012 ). Weight loss has been shown to improve glycemic control 
and to reduce the severity of diabetes -associated comorbidities, supporting the view that anti -
diabetic agents that promote weight loss may be particularly beneficial for the treatment of 
the disease (Look, Wing et al. 2013 ; Scheen and Van Gaal 2014 ). Several classes of agents 
are available for treating T2DM , including insulin and its secretagogues , such as 
sulfonylureas (SU) , PPAR agonists, biguanides, alpha glucosidase inhibitors, glucagon -like 
peptide 1 (GLP -1) receptor agonists , meglit inides,  dipeptidyl peptidase 4 (DPP4) inhibitors , 
and sodium glucose linked transporter 2 inhibitors (SGLT2i) .  Metformin is the first line 
medic ation f or treating T2DM; however, as T2DM  progresses  over time , metformin 
monotherapy is not able to adequately manage hyperglycemia. T2DM  patients often receive 
more than one antidiabetic medication  after an initial treatment period of metformin 
monothera py. DPP4 inhibitors  are considered second -line therapy for T2DM in clinical 
practice and are often prescribed with metformin as a combination therapy for treating 
T2DM. Sitagliptin is a DPP -4 inhibitor, which prevents the degradation of incretin. Incretin 
increases insulin production and reduces hepatic glucose production, leading to better 
glucose metabolism. Sitagliptin is primarily excreted unchanged in the urine. DPP4 inhibitors  
can reduce the risk of long -term microvascular complications via effective glycemic control  
and do  not have weight gain or increased hypoglycemia risk compared with placebo.  
The rapid growth rate in the incidence of T2DM has led to an increasing recognition that 
additional therapeutics are needed to provide safe and effective red uctions of elevated plasma 
glucose levels . New agents to treat T2DM, either as monotherapy or add -on therapy to other 
anti-diabetic medications, would ideally treat hyperglycemia and avoid common side effects 
of currently available agents, such as weight g ain, gastrointestinal disturbance, and 
hypoglycemia.  
The renal Na+/glucose transport protein SGLT2 actively transports extracellular glucose into 
cells using the driving energy of the transmembrane electrochemical potential for sodium 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 15 of 69 Global Versio n 2.0 ions. Individuals wit h disruptions in SLC5A2 , the gene encoding SGLT2, exhibit prominent 
glucosuria in the absence of significant co -morbidities (van den Heuvel, Assink et  al. 2002 ; 
Santer, Kinner et al. 2003 ). The excre tion of glucose in the urine of diabetic subjects in 
amounts comparable to or greater than that seen in individuals harboring loss of function 
mutations in SLC5A2  has the potential to improve fasting and postprandial hyperglycemia 
without increasing insuli n secretion, causing weight gain, or inducing hypoglycemia. Several 
SGLT2 inhibitors have demonstrated these clinical benefits , as well as sustained weight loss , 
when used as a monotherapy or in combination with other oral anti -diabetic medications 
includi ng insulin (Nauck 2014 ; Seufert 2015 ). 
1.2  Bexagliflozin  for the Treatment of Type 2 Diabetes Mellitus 
Bexagliflozin is a candidate oral hypoglycemic agent (OHA) that is a potent and highly 
specific inhibitor of SGLT2. It was identified following a synthetic program aimed at 
creating molecules with high selectivity and potency for SGLT2 (Zhang, Welihinda et al. 
2011 ). Bexagliflozin has been shown to cause dose -dependent increases in urinary glucose 
excretion (UGE) in humans, rats, dogs , and monkeys and to reduce HbA1c in animal models 
of T2DM as well as in diabetic subjects. In a 12 week monotherapy  study, bexagliflozin  
tablets, 20 m g, showed greater placebo adjusted HbA1c  reduction ( -0.80%) than 
bexagliflozin, 10 mg ( -0.68%) , and bexagliflozin , 5 mg (-0.55%). Bexagliflozin 
administration has been well tolerated. The safety and efficacy of bexagliflozin tablets , 
20 mg, were evaluated in a 96 -week study that measured reduction in hemoglobin A1c  
(HbA1c)  as the primary endpoint.  This 96 week study showed bexagliflozin tablets, 20 mg , 
to be superior to placebo in reducing HbA1c.   Details of the pharmacology, efficacy, and 
safety assessmen ts are described in the Investigator’s Brochure.  The safety profile supports 
continue d evaluation of the treatment effect when used in combination with metformin.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 16 of 69 Global Versio n 2.0 2 STUDY OBJECTIVES  
2.1 Primary Objective  
The primary efficacy objective of this trial is to demonst rate that bexagliflozin is non -inferior 
to sitagliptin  by evaluating the treatment effect  on HbA1c reduction at week 24  in subjects 
whose T2DM is inadequately controlled by metformin . 
2.2 Key Secondary Objective s 
• To evaluate the treatment effect of bexaglifloz in vs. sitagliptin on the change in fasting 
plasma glucose (FPG) at week 24  
• To evaluate the treatment effect of bexagliflozin vs. sitagliptin  on the change in body 
weight in subjects with baseline body mass index (BMI) ≥  25 kg/m2 at week  24 
• To evaluate th e treatment effect of bexagliflozin vs. sitagliptin  on the change in systolic 
blood pressure (SBP) in subjects at week 24  
 
2.3 Exploratory Objectives  
• To assess the treatment effect of bexagliflozin vs . sitagliptin  on the change in the 
proportion of subjects ac hieving HbA1c < 7.0% over time  
• To assess the treatment effect of bexagliflozin vs . sitagliptin  on the change in HbA1c 
over time  
• To assess  the treatment effect of bexagliflozin vs . sitagliptin  on the change in FPG over 
time  
• To assess the treatment effect o f bexagliflozin vs. sitagliptin  on the change in body 
weight over time   
• To assess the treatment effect of bexagliflozin vs. sitagliptin on the change in SBP over 
time 
 
Safety Objectives:  
• To compare the effects of bexagliflozin vs. sitagliptin  on the incide nce of adverse events  
(AE)  of interest. AE of interest are urinary tract infections including urosepsis and 
pyelonephritis, genital mycotic infections  (GMI) , diuretic effects including hypovolemia, 
hypotension episodes, hypoglycemia, hepatotoxicity, major adverse cardiovascular events 
(MACE), falls and fractures, malignancies, hypersensitivity reactions, acid -base disorders 
including diabetic ketoacidosis  (DKA) , amputations, pancreatitis,  and renal failure events  
• To compare the effects of bexagliflozin vs. sitagliptin  on general safety assessments 
including treatment emergent AE, clinical laboratory events, 12 -lead electrocardiograms 
(ECG) parameters, physical examinations, vital signs including orthostatic blood 
pressure (BP) , and use of concomitant medicati ons 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 17 of 69 Global Versio n 2.0 3 INVESTIGATIONAL PLAN  
3.1 Overall Study Design and Plan  
THR -1442 -C-423 is a phase 3, multi -center, randomized, dou ble-blind , parallel -group study  
and aims to demonstrate that bexagliflozin is non -inferior to sitagliptin  as add -on therapy  in 
subjects  whose T 2DM is not adequately controlled by me tformin treatment . The primary 
efficacy endpoint  is the change in H bA1c from baseline at week 24 . The study will enroll 
T2DM patients who  are treated with only metformin.  
All subjects must have taken metformin at a sta ble dose of ≥ 1500  mg/day for ≥  8 weeks 
prior to screening  and have received diet and exercise counseling .  
A total of 374 subjects who  meet all the inclusion criteria, none of the exclusion criteria, and 
who consent to participate in the study , are eligib le for study enrollment.  Subjects who  
successfully  complete a 1-week run -in and who meet all eligibility criteria will be 
randomized in a 1:1 ratio to receive once daily double -blind treatment of either active 
bexagliflo zin tablets  with placebo sitagliptin  tablets  (Group 1) or placebo bexagliflozin 
tablets and active sitagliptin  tablets  (Group 2). Active treatment in Group 1 will be 
bexagliflozin  tablets, 20 mg . Active treatment in Group 2 will be sitagliptin  tablets , 100 mg. 
Study subjects will continue re ceiving open -label ed metformin background medication  
during the entire study  at a stable dose and frequency . The treatment period will last  24 
weeks  and be conduc ted in an outpatient setting . 
3.2 Research Methods and Procedures  
3.2.1  Run-in Period  
All subjects who a re eligible at the screening visit will begin a 1 week run -in period. At the 
start of the run -in period, subjects will receive diet and exercise counseling as well as  
instructions on contacting the clinic in the event of hyperglycemia, hypoglycemia , or 
symptoms that may suggest ketoacidosis . At the start of run -in, subjects will be provided 
with a glucometer and instructions for its daily use. During the run -in, subjects will receive 
placebo bexagliflozin and placebo sitagliptin . Bexagliflozin tablets  and s itagliptin tablets will 
be taken  with water at the same time everyday . Metformin dose and frequenc y will remain 
unchanged from time of screening throughout the course of the study.  
Subjects will not be eligible for randomization if during  the run -in period  they:  
1. have fasting blood glucose values  ≥ 250 mg/dL on two or more consecutive days, 
accompanied by symptoms of hyperglycemia  
2. omit more than 1 day of run-in medication , or 
3. are deemed inappropriate for the study by the investigator ,  
 
Inclusion and exclus ion criteria are described in more detail in sections 4.2 and 4.3. 
 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 18 of 69 Global Versio n 2.0 Changes in the dose of treatment for dyslipidemia or hypertension will not be permitted 
during the screening a nd run -in periods.  Management of concomitant medications is 
described in Section 5. 6 Concomitant Therapy .  
If a change in treatment for hypertension or dyslipidemia is deemed necessary by the 
investigator for the wel l-being of the study subject during the run-in period , the subject will 
be considered as screen failed and discontinue study activities; there will be no opportunity to 
re-screen for subjects who have started run -in and screen failed.   
3.2.2  Treatment Period  
The double -blind treatment period will start at randomization and last 24 weeks. A total of  
374 subjects of 187 subjects per group will be randomized in a 1:1  ratio to the two groups  as 
shown in Table 1 .  
Table  1. Treatment Groups and Assigned Treatment  
Treatment Group  Treatment  
1 Bexagliflozin  tablets, 20 mg , (once daily P.O.)  
Sitagliptin  tablets , placebo , (once daily P.O.)  
2 Bexagliflozin tablets, placebo,  (once daily P.O.)  
Sitagliptin  tablets , 100 mg, (once daily P.O.)  
 
Randomization will be stratified by HbA1c at Visit V1 (≤ 8.5% vs. ˃ 8.5%) at screening . At 
the start of the treatment period, each subject will be provided  with bexagliflozin tablets, 
sitagliptin  tablets , and dosing instruction s. Symptoms and blood sugars  related to th e 
occurrence of hyperglycemi a, hypoglycem ic events , or symptoms that may suggest 
ketoacidosis will be recorded.  Bexagliflozin tablets, 20 mg or placebo , and sitagliptin tablets, 
100 mg or placebo , will be taken once daily at approximately the same time each day either 
before or after breakfast  with ap proximately one cup (250 mL) of water.  Background 
metformin shall be taken at the same  dose and frequency  from  screening  throughout the 
entire study.  
Each subject will be instructed t o return to the clinic at weeks 6, 12, 18 and 24 for efficacy 
asses sment  and safety monitoring, including review of AEs and concomitant medication, 
vital signs, ECG, physical examination, and blood and urine specimen collections. On the 
day of a clinic visit  at which blood samples are scheduled to be collected , approximat ely 10 
hours (h) fasting must be confirmed prior to blood draw.  On the day of the scheduled clinic 
visits at which there is fasting and blood is to be drawn , administration of bexagliflozin  and 
sitagliptin  shall be wit hheld until after blood is drawn  and t aken with water at the clinic  or 
home.  
Subjects will return to the clinic for a  follow -up exit visit at week 26 or 2 week s after the last 
dose of study drugs  if subject s early terminate  prior to week 24 . Following the exit visit, 
subjects will be advised t o see their primary physician to undergo treatment to control their 
diabetes.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 19 of 69 Global Versio n 2.0 3.2.3  Glycemic Control Monitoring  
3.2.3.1  Placebo Run -in Period  
During placebo  run-in period, subjects will be instructed to determine self-monitored blood 
glucose ( SMBG ) daily after fasting o vernight for approximately  10 h. Subject s should 
contact the clinic  if any fasting glucose value is  ≥ 250 mg/dL (13.9 mmol/L) , and the 
investigator will determine whether the participant should attempt to improve diet and 
exercise  to maintain glycemic cont rol or if the participant must withdraw from the study and 
initiate a more intense pharmacological regimen for glucose control.   
A subject will be excluded from further participation if the SMBG  is ≥ 250 mg/dL  on 2 
consecutive days , and is accompanied by s ymptoms of hyperglycemia.  Subjects with clinical 
signs or symptoms of severe hyperglycemia  during the run -in period , including weight loss, 
blurred vision, increased thirst, increased urination, or fatigue , should also be excluded.  
3.2.3.2  Treatment Period  
During the treatment period, subjects will be advised to continue daily, fasting SMBG 
measurements. Subjects should contact the clinic if any fasting SMBG is ≥  270 mg/dL  
(15 mmol/L ) from week 0 to week 6, ≥  240 mg/d L (13.3 mmol/L ) after week 6 to week 12, 
or ≥ 200 mg/d L (11.1 mmol/L ) after week 12.  Blood glucose values collected via SMBG will 
be evaluate d at study visits by the investigator. In addition, hyperglycemia will be monitored 
by FPG at scheduled  visits. 
If hyperglycemia is identified through SMBG or FPG measurements, t he investigator will 
determine whether the subject has fasted for approximatel y 10 h prior to the morning blood 
draw to ensure  that the SMBG or FPG value is truly a fasting sample. If proper fasting has 
not occurred,  the subject  will be asked  to return for a r epeat blood test within a week.  
During the treatment period, hyperglycemia  should be managed  first with diet and exercise 
counseling . If hyperglycemia continues after diet and exercise counseling, the investigator 
may prescribe rescue medication  if it is necessary for the well -being of the subject . 
3.2.3.3  Rescue Medication  
Rescue medic ation  is suggested during the treatment period if , after diet and exercise 
counseling,  subjects meet the following glycemic criteria :  
1. More than 3 consecutive, daily, fasting SMBG meas ures are ≥ 270 mg/dL  (15 mmol/L ) 
from baseline  to week 6, ≥  240 mg/dL  (13.3 mmol/L ) from  week 6 to week 12, or 
≥ 200 mg/dL  (11.1 mmol/L ) or HbA1c >  8.0% from  week 12 to week 24  
2. Fasting SMBG values  are ≥ 250 mg/dL  (13.9 mmol/L ) and associated with clinical signs 
or symptoms of hyperglycemia (e.g., weight  loss, blurred vision, increased thirst, 
increased urination, or fatigue), and the signs or symptoms are severe . 
 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 20 of 69 Global Versio n 2.0 If a rescue medication for hyperglycemia is to be prescribed, a blood sample must be drawn 
prior to the administration of the rescue medication so that a final HbA1c value can be 
ascribed to the latest date upon which the subject ’s glycemic control will be impacted by the 
rescue medication . 
The investigator may provide rescue treatment with any app roved medication for diabetes 
that is not otherwise contraindicated . Other  SGLT2 inhibitor s (Appendix 3 ), DPP-4 
inhibitors , or GLP -1 agonists  may not be prescribed.  Metformin dose can be increased at  the 
discretion of the investigator . SUs and insulins are known to increase the risk of 
hypoglycemia in combi nation with sitagliptin. As subjects  may be taking active sitagliptin, 
investigators should use caution in prescribing these medications.  
If hypogl ycemia occurs in any subject who has been prescribed rescue medication for 
hyperglycemia during the study, the total daily dose of the rescue medication should be 
reduced 50% or more at the discretion of the investigator. If recurrent symptomatic 
hypoglyce mia occurs after discontinuation of the rescue medication , the study drug can be 
discontinued at the discretion of the investigator.  
If recurrent symptomatic hypoglycemia occurs in subjects who are not prescribed rescue 
medication, the total daily dose of metformin should be decreased at the discretion of the 
investigator. If recurrent symptomatic hypoglycemia continues after decreasing the dose of 
metformin, subjects should be discontinued from the study and treated in accordance with 
local standards of ca re. 
Subjects  who receive rescue medication due to poor glycemic control will continue to receive 
investigational product s and standard of care per investigator decision, according to current 
treatment guidelines . Following the exit visit, subjects  will be advised to see their primary 
physician to undergo treatment  to control their diabetes.  
3.2.4  Other Safety Monitoring Activities  
The safety monitoring activities will include assessment s of vital signs, 12-lead ECG, 
physical examinations, urinalysis, blood chemi stry, hematology, AEs, and concomitant 
medication use . The occurrence of blood, liver, or skin disorders will be monitored through 
laboratory testing and evaluation of AE documentation.  
Sitagliptin  treatment may increase the risk of developing acute pancr eatitis, acute  renal 
failure, hypersensitivity  reactions, and arthralgia . Subjects experiencing these conditions 
should be immediately discontinued from  taking bexagliflozin tablets  and sitagliptin tablets  
and treated in accordance with local standards of care until the AE is resolved . The subject  
will be permanently discontinued from participation in the clinical trial if the subject ’s 
condition worsens or  if the subject starts dialysis or other renal replacement therapies.  If 
discontinued, s ubjects shoul d be advised to consult with their primary physician for 
managing T2DM .    
Sitagliptin administration should be suspended if estimat ed glomerular filtration rate  (eGFR ) 
decreases to <  60 mL/min/1.73 m2 and laboratory values should be retested within 48 h.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 21 of 69 Global Versio n 2.0 Sitagliptin dosing may resume if the eGFR returns to ≥  60 mL/min/1.73 m2.  If eGFR 
remains below 60 mL/min/1.73 m2, the subject should discontinue from participation in the 
clinical trial and be advised to see their primary physician to undergo treatment to control 
their diabetes and other medical conditions.  
AEs of special interest as defined in the statistical analysis plan will include any clinical 
signs and symptoms that indicate adverse experience in the categories listed below. All such 
events must b e appropriately documented within source documentation.  
• Acid -base disorders including DKA  
• Amputations  
• Diuretic effects including hypovolemia  
• Falls and fractures  
• GMI  
• Hepatotoxicity  
• Hypersensitivity reactions  
• Hypoglycemia  
• Hypotension episodes  
• MACE  
• Malignanci es 
• Pancreatitis  
• Renal failure events  
• Urinary tract infections including urosepsis and pyelonephritis  
 
3.2.5  Data and Safety Monitoring Board (DSMB)  
An independent Data and Safety Monitoring Board (DSMB) will monitor overall safety 
information during the bexagli flozin  development program. The safety review activity and 
potential risk benefit assessments utilized by the DSMB will be defined in its charter.  
3.2.6  Major Adverse Cardiovascular Event (MACE) Adjudication  
An independent cardiovascular adjudication committee has been  established to review,  under 
blind,  all potential cardiovascular events occurring during the study . The events of interest 
include cardiovascular mortality, myocardial infarction  (MI) , stroke, hospitalization for acute 
coronary syndromes, urgent r evascularization procedures, and other possible serious 
cardiovascular events . The adjudicated events will be documented and archived to allow a 
meta -analysis to be performed at a later time . No separate cardiovascular risk assessment will 
be performed bas ed on events in the study population of the current protocol.  
3.2.7  Diabetic Ketoacidosis (DKA) Event Adjudication  
An independent adjudication committee will be established to review all potential DKA 
under blind. The adjudicated events will be documented and a rchived. All adjudicated DKA 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 22 of 69 Global Versio n 2.0 events in the bexagliflozin phase 3 program will be pooled at the end of the program and a 
final analysis will be conducted.   
3.3 Rational for Study Design and Procedures  
3.3.1  Rationale for the Study Design  
THR -1442 -C-423 is designed  to assess the non -inferiority of bexagliflozin to sitagliptin as 
add-on therapy to metformin for glycemic control in T2DM subjects . To assess the effect of 
bexagliflozin or sitagliptin  in addition to an effective dose of metformin background therapy, 
all sub jects must be taking a stable dose of ≥ 1500 mg metformin daily  for at least 8 weeks 
prior to screening . If a potential subject has taken <  1500  mg/day metformin, the subject can 
enter screening once the dose of metformin has been  be increased to at least 1500 mg/day for 
at least 8 weeks. Chan ges in the dose of metformin will not be permitted at any time during 
the study  unless persistent hypoglycemia occurs during the treatment period .  
Diet and exercise counseling will be provided to all participating subjects to reduce risks of 
worsening dia betic conditions. A monitoring plan and criteria to initiate rescue medications 
are included in the protocol  to prevent prolonged hyperglycemia.  
Reduction in HbA1c directly reflects improvement in glycemic control and is considered a 
well-validated surrog ate for the long -term microvascular complications of diabetes mellitus .  
3.3.2  Rationale for Background Medication and Active Comparator  
Metformin is the most commonly prescribed OHA and is recommended as first -line therapy  
for the treatment of T2DM.  It is a big uanide that decreases hepatic glucose production and 
may improve peripheral glucose uptake and utilization.  
Subjects who have T2DM often require multiple anti -diabetic medications for glycemic 
control. DPP -4 inhibitors are often prescribed with metformin a s a combination therapy for 
treating T2DM. DPP -4 inhibitors can reduce the risk of long -term microvascular 
complications via effective glycemic control.  Sitagliptin in addition to metformin does not 
have additional risk of hypoglycemia. Sitagliptin is one of the most commonly prescribed 
DPP-4 inhibitors. Thus, it is an appropriate active comparator in the subject population 
studied during the treatment period (24 weeks).  
Bexagliflozin is an SGLT2 inhibitor developed for the treatment of T2DM that reduces 
hyperglycemia via an insulin -independent pathway of inhibiting glucose re -uptake and 
promoting urinary glucose excretion. Individuals treated with metformin and with inadequate 
glycemic control have reduced HbA1c, reduced body weight, and less incidence of 
hypoglycemia when treated with approved SGLT2 inhibitors canagliflozin, dapagliflozin or 
empagliflozin. Thus T2DM subjects on metformin therapy with inadequate glycemic control 
may benefit from combination treatment with bexagliflozin.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 23 of 69 Global Versio n 2.0 3.3.3  Rationale for the Dos e Selection  
Bexagliflozin produces a dose -dependent and saturable increase in UGE in healthy 
volunteers and subjects with T2DM. Population pharmacodynamic modeling has indicated 
that bexagliflozin doses of 20 mg result in approximately 90% of the maximal U GE. In a 12 -
week dose range finding study, daily administration of 20 mg bexagliflozin was found to 
reduce HbA1c by 0.80% compared to placebo at week 12, a greater reduction than found in 
10 mg and 5 mg cohorts. A higher proportion of patients that have be en treated with 
bexagliflozin tablets at 20 mg per day has achieved the target of HbA1c below 7%.  FPG 
reduction, weight loss, and decreased systolic and diastolic BPs compared to baseline were 
also observed following 12 weeks of treatment.  In addition, AEs, particularly those 
involving urinary tract infections  (UTI) and GMI s, were found to be similar between placebo 
and active agent cohorts. To evaluate the safety and efficacy of bexagliflozin compared to 
sitagliptin for the treatment of subjects with T2DM , bexagliflozin tablets, 20 mg , will be 
administered in this trial.  
3.4 Study Duration and Dates  
Subjects will be enrolled within  2 weeks of screening . Eligible subjects who provide written 
consent will start a run-in period of 1 week prior to randomization to  receive study drugs  to 
demonstrate compliance . Subjects who successfully complete the run -in will begin  24 weeks  
of treatment and will be followed  for 2 weeks after the last dosing . The study duration from 
screening to follow -up will be no more than 29 weeks overall. For details of the schedule and 
nature of the investigations, see the Schedule of Events in Appendices 1  and 2.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 24 of 69 Global Versio n 2.0 4 STUDY POPULATION S ELECTION  
4.1 Study Population  
The study population will include approximately  374 subjects  whose T2DM  is inade quately 
controlled by metformin and who meet all of  the inclusion criteria  and none of the exclusion 
criteria . Clini cal sites in the North America and  Europe are anticipated to recruit subjects . 
4.2 Inclusion Criteria  
Prospective subjects must be:  
1. Male or female adult subjects ≥ 18 years of age  
2. If subjects are female of childbearing potential , subjects  must be negative on the urine 
pregnancy test and agree to abstain from coitus or use contraception  during the entire 
study  
3. Subjects with a diagnosis of T2DM with HbA1c levels between 7.0% and 11% 
(inclusive) at screening  
4. Subjects whose T2DM is treated with a stable dose of ≥ 1500  mg/day metformin  only 
along wi th diet and exercise counseling for at least 8 weeks prior to screening  
5. Subjects have a BMI ≤ 4 5 kg/m2 at screening  
6. If applicable, taking stable doses of treatment for dyslipidemia and/or hypertension for 30 
days prior to screening  
7. Subjects who are willin g and able to return for all clinic visits and to complete all study -
required procedures, including SMBG measurements  
 
Prior to randomization, all subjects must : 
8. Adhere to the investigational product administration requirements as evidenced by 
missing no m ore than 1 day  of run -in medication s. If run -in medication doses are missed 
for reasons that , in the judgement of the investigator, are appropriate, this requirement 
may be waived  
 
4.3 Exclusion Criteria  
Subjects who exhibit any of the following characteristic s will be excluded from the study:  
1. Diagnosis of type 1 diabetes mellitus or maturity –onset diabetes of the young (MODY)  
2. Hemoglobinopathy that affect s HbA1c measurement  
3. Any contraindication to the safe use of DPP4 therapy or sitagliptin , including known 
hypersensitivity reaction   
4. History of pancreatitis  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 25 of 69 Global Versio n 2.0 5. Genitourinary tract infection within 6 weeks of screening or history of ≥  3 genitourinary 
infections requiring treatment within 6 months from screening  
6. Cancer , active or in remission , for < 3 years (non -melanoma skin cancer or basal cell 
carcinoma or carcinoma  in situ  of the cervix will not be grounds for exclusion)  
7. History of alcohol or illicit drug abuse in the past 2 years  
8. Triglycerides > 500 mg/dl at Visit V1  
9. Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 x 
upper limit of normal (ULN) with the except ion of isolated Gilbert’s syndrome); or 
alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULN  
10. eGFR, as calculated by the modification of diet in renal diseas e study equation (MDRD), 
< 60 mL/min/1.73 m2 at screening . 
11. Uncontrolled hy pertension ( SBP > 160 mmHg or diastolic BP > 95 mmHg) at Visit V1  
12. Life expectancy < 2 years  
13. History of MI , unstable angina, stroke, or hospitalization for heart failure within 3 months 
of screening  
14. History of t reatment with an investigational drug within 3 0 days or within 7 half-lives  of 
the investigational drug, whichever is longer  
15. Previous treatment with bexagliflozin or EGT0001474  study drug ( run-in or double -blind 
investigational product)  
16. Currently or within 3  months of taking any SGLT2 inhibitor  (Appendix 3 ) 
17. Currently participating in another interventional trial  
18. Prior renal transplantation or evidence of nephrotic syndrome (defined as a urine 
albumin -to-creatinine ratio (UACR) > 1500  mg/g at scre ening).  
19. Any condition, disease, disorder, or clinically relevant abnormality that, in the opinion of 
the primary investigator, would jeopardize the subject’s appropriate participation in this 
study or obscure the effects of treatment  
20. Female subjects who ar e pregnant or nursing  
21. Two or more consecutive  SMBG  measures ≥ 250 mg/dL (13.9 mmol/L) prior to 
randomization accompanied by  clinical signs or symptoms of hyperglycemia prior to 
randomization , including weight loss, blurred vision, increased thirst, increas ed urination, 
or fatigue  
 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 26 of 69 Global Versio n 2.0 5 STUDY TREATMENTS  
5.1 Description of Treatment s 
5.1.1  Investigational Product  
Bexagliflozin tablets, 20 mg or placebo, are blue caplet -shaped, film -coated tablets that are 
intended for use in investigational studies in humans. The tablets co ntain excipients designed 
to promote extended release through a gastroretentive mechanism. The active tablets exhibit 
a greater than 75% re lease of drug substance by 8 h in simulated gastric fluid in vitro .  
The following investigational products will be u sed for oral administration:  
• Bexagliflozin tablets, 20 mg: tablets containing 20 mg of bexagliflozin  
• Bexagliflozin tablets, placebo: tablets containing no bexagliflozin  
 
5.1.2  Active Comparator  
Sitagliptin tablets, 100 mg or placebo, are beige, round, film -coate d tablets with “277” on 
one side.  
The following active comparator products will be used for oral administration:  
• Sitagliptin tablets, 100 mg: tablets containing 100 mg of sitagliptin  
• Sitagliptin tablets, placebo: tablets containing no sitagliptin  
 
5.2 Treatmen ts Administered  
5.2.1  Investigational Product  
Bexagliflozin tablets, 20 mg or placebo, should be taken  at approximately the same time each 
day, before or after breakfast, with  one cup ( 250 mL ) of water . 
On the day of scheduled clinic visits when there is fasting  and blood is to be drawn , 
administration of bexagliflozin should be delayed until after blood is drawn  and taken in the 
clinic  or at home  with one cup ( 250 mL ) of water . 
5.2.2  Active Comparator  
Sitagliptin  tablets , 100 mg or placebo, should be taken once daily at the same time as 
bexagliflozin , before or after breakfast, with one cup (250 mL) of water .  
On the day of scheduled clinic visit s when there is fasting and blood is to be drawn , 
administration of sitagliptin  should be delayed  until after blood is drawn  and taken in the 
clinic or at home with one cup (250 mL) of water . 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 27 of 69 Global Versio n 2.0 5.2.3  Background Metformin Therapy  
Subjects will continue receiving metformin as background therapy during the entire study 
period at an unchanged dose (≥  1500 mg/day ), time, and frequency as prescribed to subjects 
prior to screening.   
The dose, frequency, and time of administration should remain stable unless the investigator 
deems  adjustment (decrease or increase) necessary for the medical well -being of the subject.  
Guidance for adjustment to metformin dose is provided in Section 3.2.3. Changes to the dose, 
frequency, or time of admin istration of metformin should be recorded in the concomitant 
medication log.  
5.3 Selection and Timing of Dose for Each Patient  
5.3.1  Bexagliflozin  
Dosing with bexagliflozin tablets, 20 mg or placebo, will be based on randomized  
assignment  at the beginning of the tre atment period . All study subjects will be instructed to 
take bexagliflozin tablets once daily in  the morning, before or after breakfast , with one cup 
(250 mL) of water.  The dose and frequency  of bexagliflozin will be unchanged during the 
24-week treatment period.  
On the day of each scheduled clinic visit, subjects must fast for approximat ely 10 h prior to 
the collection of blood samples. During the fasting period, only water will be permitted.   
5.3.2  Sitagliptin  
Dosing with sitagliptin  tablets , 100 mg or placebo , will be based on randomized assignment  
at the beginning of the treatment period . All study subjects will be instructed to take 
sitagliptin tablets once daily in the morning , before or after breakfast, with one cup (250 mL) 
of water . The dose of sitaglipt in will be unchanged during the 24-week treatment period.  
5.4 Method of Assigning Treatment Groups  and Study Drugs  
The study will be conducted at multiple investigative sites and will involve variable num bers 
of subjects at each site. Enrollment will be on a c ompetitive basis , but each site will be 
capped at 30 randomized  subjects . Activation of investigational sites in each country will be 
centrally controlled  by an Interactive Web Response System ( IWRS ). 
Eligible subjects who complete the run -in period  and me et all study inclusion/exclusion 
requirements will be randomized  in a 1:1 ratio to receive active bexagliflozin  with placebo 
sitagliptin  or active sitagliptin  with placebo bexagliflozin . Subjects will be assigned to 
treatment groups in sequential order as they qualify for the study . Randomization will be 
stratified according to screening  (Visit V1) HbA1c (< 8.5% or ≥  8.5%) . The investigator or 
designated staff will log into the IWRS to receive the randomization code and assigned kit 
numbers . 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 28 of 69 Global Versio n 2.0 Subject randomi zation will be deactivated for all sites when the planned number of subjects  
(N) is met . However, if a potential subject has been screened  already and wishes to continue 
with the study, the subject will be allowed to continue and, if eligible, to be random ized. 
5.5 Blinding  
This is a double -blind, double dummy study. The sponsor, investigators, study coordinators, 
pharmacists,  study subjects, the cardiovascular  endpoint c ommittee  (CEC ), and the DKA  
committee will be blinded to the study medication s.  
To maintai n blinding of the individual treatment assignment , the results of urinary glucose 
testing will not be made available to any study personnel or subjects.  If knowledge of the test 
results is needed to manage a subject’s condition, the investigator will conta ct the IWRS to 
obtain the treatment assignment. If unblinding occurs for any reason, the time and reason for 
breaking the blind will be recorded on the case report form (CRF) and the sponsor must be 
notified within 24 h.  
A designated statistician who is n ot involved with the study operation will hold the treatment 
code s. The unblinded treatment information can be provided to the DSMB to facilitate the 
evaluation of any clinically important increase in the rate of a serious suspected adverse 
reaction or to the designated safety contact when the treatment information is required to 
determine if an expedited safety report must be submitted to regulatory agencies .  
The treatment assignment will continue to be withheld from the CEC  and DKA  adjudication 
committee  members  until all global investigational studies are completed and  final analyses 
to assess cardiovascular and ketoacidosis risks are conducted.  
5.6 Concomitant  Therapy  
During the course of the study , investigators will manage glucose, BP, and lipid levels 
according to local or regional  standard of care guidance documents for the management of 
T2DM. Instructions for rescue medication  for hyperglycemia are  provided in Section 3.2.3.3. 
Subjects will be allowed to take medicat ions or medicinal supplements prescribed to manage 
non-diabetic medical conditions during the study. Any conc urrent medication or 
supplemental treatment of other, non -diabetes, medical  conditions should be continued at a 
stable dose and frequency for the e ntire study duration unless there is a clinical reason to 
change the dose or frequency.  
Subjects may receive any medications for AEs that are necessary in the investigators’ 
judgment. Medications prescribed after the informed consent  are to be recorded on  the CRF. 
The medication name, dose, frequency, route of administration, date(s) of administration , and 
reason for administration must be recorded. This documentation should continue through the 
treatment period and the follow -up period.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 29 of 69 Global Versio n 2.0 5.6.1  Diuretics and Med ications for Treatment of Dyslipidemia and Hypertension  
Subjects who are prescribed diuretics, anti -hypertensive agents, or medications to treat 
dyslipidemia will continue the current dose, frequency, and time of administration of these 
medications through out the study. Subjects do not need to be treated with dyslipidemia or 
hypertension to be eligible for the study.  Adjustment of these medications will not be 
permitted during the screening and run -in periods.  
If a change in diuretics, anti -hypertensive ag ents, or medications to treat dyslipidemia is 
required during the screening period, the subject will discontinue study activities and may be 
re-screened after the clinical condition and treatment regimen have been stable for at least 30 
days.  
If a subject  re-enters screening after treatment adjustment, a new subject number will be 
assigned. During the treatment period, adjustments in the treatment for hypertension or 
dyslipidemia are permitted if required for the well -being of the subject. New  diuretic 
medications should not be initiated during the first 2 weeks of the treatment period.  The dose 
and frequency of existing diuretic medications should not be changed during the first 2 weeks 
of therapy. Changes to the dose or frequency of anti -hypertensive and diuretic medications 
will be recorded in the concomitant medications log.  
5.7 Restrictions  
5.7.1  Prior Therapy  
All subjects will continue regimens for medical conditions other than diabetes during the 
study as indicated above . No subject shall have been treated with  an investigational drug 
within 30 days of screening or within a period equal to less than 7 half -lives of the 
investigational drug , whichever is longer. No subject shall have been treated w ith an SGLT2 
inhibitor within 3 months of screening.  Subjects taki ng any hypoglycemic agents other than 
metformin during the  8 weeks  prior to  screening are not eligible for this study.  
5.7.2  Fluid and Food Intake  
During the study, subjects will be counseled to remain adequately hydrated at all times. In 
addition, subjects wil l receive counseling regarding an appropriate diet to achieve glycemic 
control based on standard s of medical care in diabetes. For example, t he recommended diet 
might be low in saturated fat, high in fiber, low in simple carbohydrates , and contain 
appropri ate caloric intake to maintain weight . Subjects will also be counseled consume 
alcohol in moderation. Subjects with a known history of alcohol abuse should be excluded 
from the study as indicated in Section 4.3 . 
Subje cts will fast for approximately  10 h prior to the scheduled blood sample draws. During 
fasting, only water will be permitted.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 30 of 69 Global Versio n 2.0 5.7.3  Subject Activity Restrictions  
Throughout the study period, subjects are counseled and encouraged to engage in a level of 
physical activity  that is appropriate for their physical condition. For those without specific 
restrictions or limitations, at least 150 min/week of moderate activity  is advised by the 
American Diabetes Association (ADA) (American Diabetes, 2014 ). Alternatively, lo cal 
regulatory  guidelines may be used.  
5.8 Treatment Compliance  
Subjects will be provided with  dosing instructions when the investigational products  are 
dispensed. Subjects will also be instructed to bring their medication s with them at every visit . 
During the  run-in period, subjects will be excluded from  randomization if more than  1 day of  
placebo run -in medication doses has been omitted.  If, in the judgement of the investigator, it 
was appropriate for the subject to omit these doses, this requirement may be w aived (e.g., if 
the subject was hospitalized overnight during run -in). 
At each visit after the start of the run -in period, the study staff will review SMBG diary and 
medication s use with the subject and record the drug consumption  in the CRF. Reasons for 
non-adherence will also be recorded in the protocol deviation log if applicable.  
5.9 Packaging and Labeling  
Investigational product s will be provided to the pharmacist or designated s ite personnel in 
high-density polyethylene ( HDPE ) bottles of 90 t ablets enclos ed with a child -resistant cap. A 
bottle  of 15 bexagliflozin tablets, placebo , and a bottle of 15 sitagliptin  tablets , placebo, will 
be provided for the 1-week run -in portion of the study. All investigational product  supplies 
will be prepared and labeled ac cording to the requirements of local law s and regulations . The 
pharmacist or designated site personnel will dispense the investigational products  for each 
subject according  to randomization assignment.  
5.9.1  Run-in Kit s 
Two types of run -in kits are provided:  
• Bexagliflozin  tablets, placebo , 15 tablets per bottle  
• Sitagliptin  tablets , placebo , 15 tablets  per bottle  
 
The label  attached to each run -in kit will contain the protocol number, product identification,  
kit number,  batch  number, expiration date, subject num ber, investigator name, storage 
condition, directions for use, sponsor’s name and address, and the investigational drug 
caution statement.  
5.9.2  Bexagliflozin Kit 
One bexagliflozin  kit contains a 90 count bottle  of bexagliflozin table ts, 20 mg  or placebo .  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 31 of 69 Global Versio n 2.0 The l abel attached to each bexagliflozin  kit will contain the protocol number, product 
identification, kit number, batch number, expiration date, subject number, investigator name, 
storage condition, directions for use, sponsor’s name and address, and the inves tigational 
drug caution statement.  
5.9.3  Sitagliptin  Kit 
One sitagliptin  kit contains a 90 count  bottle  of sitagliptin tablets, 100  mg or placebo.  
The label attached to each sitagliptin  kit will contain the protocol number, product 
identification, kit number, ba tch number, expiration date, subject number, investigator name, 
storage condition, directions for use, sponsor’s name and address, and the investigational 
drug caution statement.  
5.10 Storage and Accountability  
Bexagliflozin  tablets  and sitagliptin  tablets  will be stored at control led room temperatures of 
below  30°C ( 86°F). The sponsor will notify the sites of the process f or returning unused 
drug. 
5.11 Investigational Product Retention at Study Site  
The investigational products will be stored in a secure area with l imited access . The drug 
storage facility must comply with the me dication storage instructions. The investigational 
products  should be stored at controlled room temperature until ready for dispensing to study 
subjects. The trial staff must record the amount  of investigational product s dispensed to each 
subject on the dosing record . To ensure adequate recordkeeping, subjects must bring all 
investigational products to each visit . The remaining tablets  will be accounted for in the CRF 
and drug consumption  forms . The procedures for obtaining drug resupply will be provided by 
the sponsor. All unused drug must be returned to a sponsor -designated depot after drug 
accountability is verified by the sponsor  or its designee.   
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 32 of 69 Global Versio n 2.0 6 STUDY PROCEDURES  
The following sections desc ribe procedures that are conducted in the protocol.  The clinical 
investigator must personally conduct or supervise the procedures that are required in the 
protocol.  Study tasks may be delegated to qualified staff after training is completed.  
Procedures that require clinical /medical knowledge must be performed by the investigator or 
qualified sub -investigators.  
6.1  Informed Consent  
Before each subject is enrolled in the clinical study, written informed consent will be 
obtained according to the regulatory a nd legal requirements of the participating country. As 
part of this procedure, the investigator must explain orally and in writing the nature, duration, 
purpose of the study, and the action of the drug , in such a manner that the study subject is 
aware of t he potential risks, inconveniences, or AEs that may occur. The investigator should 
educate potential subjects about the scientific importance of their data and the vital role that 
their participation has for the outcome of the entire study. The subject mus t be informed that 
he/she is free to withdraw from the study at any time. He or she will receive all information 
that is required by federal regulations and the Good Clinical Practice (GCP) guidelines  of the 
International Conference for Harmonisation  (E6).  
The informed consent document must be signed and dated; one copy will be given to the 
patient, and the investigator will retain a copy as part of the clinical study records. The 
investigator will not undertake any investigation specifically required for the clinical study 
until written consent has been obtained. The terms of the consent and when it was obtained 
must also be documented.  
6.2 Screening for I/E Criteria  
At the initial screening, the investigator should review the inclusion and exclusion criteria  
based on the information collected at the screening visit. He or she should evaluate any 
change to status affecting conformance to inclusion and exclusion criteria at subsequent visits 
prior to randomization. At randomization, the investigator should conf irm the run -in drug 
compliance . 
6.3 Medical History  
The following information will be collected at the screening visit:  
6.3.1  General Demographics and Characteristics  
• Date of birth, age, sex, and race, and whether a female subject is of childbearing potential 
or not 
• Significant medical and surgical history, including dates of diagnoses , procedures and 
whether the condition is ongoing, if applicable  
 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 33 of 69 Global Versio n 2.0 6.3.2  Diabetes History  
• History of all medications used to treat diabetes (to be recorded in the concomitant 
medication for m), including start date, duration of use, and stop date, if applicable  
• History of complications due to diabetes, including nephropathy, retinopathy, 
neuropathy, non -traumatic amputations, and DKA , including date of diagnosis  
• Frequency of hypoglycemic even ts (per week) that are symptomatic or require assistance  
6.3.3  Cardiovascular Disease History  
History of cardiovascular disease , including presence of angina, congestive heart failure 
(including NYHA classification), known atherosclerotic cardiovascular disease , prior MI, 
transient ischemic attack  (TIA)  or stroke, and prior cardiac or peripheral re -vascularization 
procedures. The history should include the date of diagnosis and the current status of 
diagnosis (resolved or ongoing).  
6.3.4  Medication History  
• Use of pre scribed or non -prescribed medications, including name of medication, 
indications for usage, start and stop dates, dose, and frequency  
• Use of supplements, including over the counter drugs, vitamins, herbal preparations, and 
dietary supplements within the pa st 30 days prior to screening. Each medication history 
will include the agent used, indication for usage, start and stop dates, dose, and frequency  
 
6.4 Diet and Exercise Counseling  
Subjects will receive counseling regarding appropriate diet and exercise to a id in glycemic 
control based on standards of medical care in diabetes throughout the study. In addition, all 
subjects are encouraged to consume enough liquid to maintain adequate hydration.  
6.5 Physical Examination  
A complete physical examination will be perf ormed by the investigator at the time points 
indicated in the Schedule of Events ( Appendix 1 ). The examination will include 
measurement of body weight and a general assessment of all body systems , including the 
skin, head, ey es, ears, nose, throat, neck, heart, lungs, abdomen, lymph nodes,  vascular 
system  and extremities.  The body weight must be determined using a scale that is calibrated. 
The same scale  should be used for the duration of the study if possible . 
6.6 Abbreviated Phy sical Examination  
An abbreviated physical examination will be performed by the investigator at the time points 
indicated in the Schedule of Events ( Appendix 1 ). An abbreviated physical examination will 
include height (only a t the screening visit)  and general assessment of the skin, heart, lungs 
and abdomen , and extremities . The body weight must be determined using a scale that is 
calibrated. The same scale should be used for the duration of the study if possible.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 34 of 69 Global Versio n 2.0 6.7 Body Weight  
The body weight will be measured at every visit except visit V2.  The weight must be 
determined using a scale that is calibrated. The same scale should be used for the duration of 
the study , if possible.  
6.8 Vital Signs  
Vital signs will be measur ed at the time points indicated in the Schedule of Events ( Appendix 
1) and will include supine, sitting , and standing BP measurements, and heart rate. Only the 
BP measured in the sitting position will be used to determine  eligibility.  
Devices designed to measure BP from the finger or wrist may not be used. The left arm and 
same cuff sizes should be used for each measurement at all visits. If the left arm cannot be 
used at the screening visit or during the study for BP measurem ents, the reason should be 
documented, and the right arm should be used for BP measurements for all subsequent visits.  
At each visit, BP measurements will be obtained using a calibrated sphygmomanometer 
while the subject is in sitting, supine, and standing  positions. A single heart rate measurement 
should be taken just prior to the BP evaluation in the sitting, supine, and standing positions.  
All readings are to be entered into the source document and CRF for all subjects. The date 
and time of BP measureme nts should be captured in the source document and CRF. BP will 
be assessed first in the sitting position. Sitting BP and heart rate will be measured after the 
subject has been sitting for at least 5 minutes with feet on the floor and arm supported at 
heart  level.  
After sitting BP measurement has been completed, supine and standing BP will be measured 
to evaluate orthostatic vital signs. Supine and standing BP measures will not be used to 
determine eligibility for the study. First, the subject will lie flat  for 5 minutes and have heart 
rate and supine BP measured using the same equipment and arm as described for sitting BP. 
Once the supine BP measurement is complete, the subject will stand. Standing BP and heart 
rate will be measured after 2 minutes of stand ing. For standing BP measurements, the arm 
should be supported and extended such t hat the cuff is at heart level.   
6.9 Electrocardiography  
A 12 -lead ECG will be conducted at the time points indicated in the Schedule of Events in 
Appendix 1  and whenever clinically indicated. This procedure should be performed in the 
supine position after at least 10 minutes of rest. ECG parameters to be recorded on the CRF 
are RR interval, PR interval, QRS duration, and QT interval. Each ECG shoul d also be 
assessed by the investigator for signs of ischemia, clinically significant hypertrophy, and 
clinically significant T -wave abnormalities or arrhythmia.  
It is the investigator’s responsibility to review the results of the ECG as they become 
availa ble. For each abnormal ECG result, the investigator shall ascertain if the observation 
represents a clinically significant change from the screening ECG for that individual subject. 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 35 of 69 Global Versio n 2.0 This determination does not necessarily need to be made the first time an abnormal result is 
observed. The investigator may repeat the ECG to verify the original result. If the ECG result 
is determined to be a clinically significant and abnormal change from baseline for that 
subject, it is considered to reflect an AE.  
6.10 Clinical L aboratory Tests  
6.10.1  Laboratory Parameters   
Clinical laboratory tests are listed in Table 2 . 
6.10.2  Sample Collection, Storage, and Shipping   
Blood samples for hematology, chemistry, serum lipids and glycemic control assessments 
will be collected. Subjects will be in a seated or supine position during blood collection. 
Samples will be collected at the time points indicated in the schedule of events in Appendix 1  
and Appendix 2 . 
The study staff will contact each subject prior to a scheduled clinic visit to confirm the time 
of the visit and to remind the subject of proper fasting practice. A subject must be queried to 
assess compliance with an approximately 10 h fast prior to blo od draw to ensure the FPG and 
triglycerides values can be accurately determined. If a subject has not fasted for 
approximately 10 h, the subject must return as soon as can be arranged (within 1 week) to 
provide a specimen after proper fasting.  
Low density lipoprotein cholesterol  (LDL -C) will be calculated by the Friedewald equation. 
If triglycerides are > 400 mg/dL, the calculated LDL -C value is invalid by this equation and 
will be set as missing. Direct LDL -C will be determined in subjects whose triglyceri des are > 
350 mg/dL at screening visit. All subsequent LDL -C of these subjects will be determined by 
the same direct LDL -C measurements only.  
An investigator can perform additional laboratory testing to diagnose or to follow up an AE 
progression or resolut ion. Clinical samples should be analyzed in a local laboratory if a fast 
turn-around time is necessary to determine treatment plan.  
6.10.3  Urinalysis  
Urine samples will be collected routinely at designated clinic visits from a clean 
catch  sample. Urinalysis will  be performed at the time points indicated in the schedule of 
events ( Appendix 1  & Appendix 2 ). The i nvestigator or study staff should document if pre -
menopausal female subjects are menstruatin g and note it in the source documents since 
hematuria is  likely to be identified on dipstick urinalysis.  
Strips  to assess leukocyte esterase and nitrite but not glucose will be provided for immediate 
assessment at the clinical sites. If more than traces of  positive results are shown in the 
leukocyte esterase and/or nitrite testing, a urine culture should be performed in a  designated 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 36 of 69 Global Versio n 2.0 laboratory regardless of patient reported signs or symptoms. Results of the urinalysis and 
possible urine culture will be docu mented in the CRFs.  
Urine samples will be transported to the central laboratory for urinalysis. Microscopy will 
be conducted if the subject has a positive result on the leukocyte esterase or nitrite dipstick 
tests to clarify the significance of the finding . Results of glucose measurement in the 
urinalysis must be suppressed from the laboratory reports so the sponsor, investigators, study 
coordinators, pharmacists, study subjects, and the CEC members will remain blinded to the 
dosing assignment.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 37 of 69 Global Versio n 2.0 6.11 Laboratory T ests 
Table 2  List of Laboratory Tests  
TEST NAME  SHIPMENT  
Hematology  Ambient  
• Hematocrit (Hct)  
• Hemoglobin (Hgb)  
• Mean corpuscular hemoglobin (MCH)  
• Mean corpuscular hemoglobin 
concentration (MCHC)  
• Platelet count  • Mean corpuscular volume (MCV)  
• Red cell distri bution width (RDW)  
• Red blood cell (RBC) count  
• White blood cell (WBC) count with differential  
  
Serum Chemistry and Electrolytes   Ambient  
• Albumin (ALB)  
• Alanine aminotransferase (ALT)  
• Alkaline Phosphatase (ALP)  
• Aspartate aminotransferase (AST)  
• Blood urea  nitrogen (BUN)  
• Glucose  
• Bicarbonate (HCO 3) 
• Creatinine  
• Chloride (Cl)  • Total protein  
• Calcium (Ca)  
• Magnesium  
• Phosphorus  
• Potassium (K)  
• Sodium (Na)  
• Total bilirubin  
• Direct bilirubin  
• Uric acid  
Glycemic Control   Ambient  
• Fasting plasma glucose (FPG)  
• Hemoglobin A1c  (HbA1c)    
Serum Lipids   Ambient  
• Total cholesterol (TC)  
• High -density lipoprotein cholesterol 
(HDL -C) 
• Triglycerides (TG)  • Low-density lipoprotein cholesterol (LDL -C), 
calculated  
• LDL -C, direct  
Urinalysis   Ambient  
• Appearance  
• Bilirubin  
• Color  
• Glucose  
• Ketones  
• Microscopic examination of sediment  
• UACR  • Nitrite  
• Occult blood  
• pH 
• Protein  
• Specific gravity  
• Urobilinogen  
• Leukocyte esterase  
Urine Pregnancy Test (WOCBP)   Local  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 38 of 69 Global Versio n 2.0 6.12 Diary and Glucometer Dispensation  
A glucometer, testing strips, and a glycemic control diar y will be provided to each subject at 
the start of the  run-in period  for SMBG. Subjects will be trained to use the glucometer and 
record any hypoglycemic  events in the glycemic control diary. The SMBG record from the 
glucometer and diary entries must be re viewed by the investigator at all subsequent visits . 
During the SMBG training, symptoms that may indicate hypoglycemia, hyperglycemia, or 
ketoacidosis will be reviewed with study subjects. Instructions to contact the clinic when the 
subjects experience pot ential hypoglycemia or DKA  must be provided.  
6.13 Dispensing Run -in Drug  
Each eligible study subject will receive one bottle of sitagliptin run -in drug and one bottle of 
bexagliflozin  run-in drug at the visit indicated  in Appendix  1. 
Patients should self -administer the first dose of each  run-in drug with 1 cup ( 250 mL ) of 
water under observation during the scheduled visit.  
6.14 Diary and Glucometer Record Review  
At each visit after the beginning  of run in, the investigator will revie w the  glycemic control 
diary, glucometer record, and symptoms that may indicate potential DKA with the subject 
and record the findings in the CRF.  
6.15 Dispensing Investigational Product  
At randomization and at every  12 weeks of treatment thereafter , each stud y subject will 
receive two bottles of the investigational product based on the kit number  assigned to the 
subject by the IWRS. One bottle will be bexagliflozin, 20  mg or placebo, and the other bottle 
will be sitagliptin, 100  mg or placebo.   Each bottle of the investigational product  will provide 
daily dosing for 12 weeks.  
Patients should self -administer the dose of investigational product with one cup ( 250 mL ) of 
water under observation during the scheduled visits, if they have not already taken 
investigati onal product that day.   
6.15.1  Drug Accountability  
To ensure adequate recordkeeping, subjects must bring all investigational products to each 
visit. The remaining tablets will be accounted for in the CRF and drug consumption  forms. 
All unused drug must be returne d to a sponsor -designated depot after drug accountability is 
verified by the sponsor or its designee.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 39 of 69 Global Versio n 2.0 6.16 Adverse Events Assessments   
6.16.1  Definition of Adverse Events   
Adverse event (AE ): Any untoward medical occurrence in a subject administered a 
pharmaceutical p roduct that does not necessarily have a causal relationship with the 
treatment.  
An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease temporally associated with the use of a medicinal 
product, whether or not it is considered related to the medicinal product use.  
Serious adverse event (SAE): A serious AE (SAE ) or reaction is any untoward medical 
occurrence that at any dose:  
• results in death  
• is life -threatening  (NOTE: The term "life -threa tening" in this context refers to an event in 
which the subject was at risk of death at the time of the event; it does not refer to an event 
which hypothetically might have caused death if it were more severe)  
• requires inpatient hospitalization or prolonga tion of existing hospitalization  
• results in persistent or significant disability/incapacity   
• is a congenital anomaly/birth defect  
• is a medically important event or reaction.  Medical and scientific judgment should be  
exercised in deciding whether a situati on should be considered serious . Important  medical 
events which  jeopardize the subject or require intervention to prevent one of the 
outcomes listed above should usually be considered serious.  Examples of such events are 
intensive treatment in an emergency  room or at home for allergic bronchospasm; blood 
dyscrasias or convulsions that do not result in hospitalization; or development of  drug 
dependency or drug abuse   
 
Adverse Reaction: An adverse reaction means any AE caused by a drug. Adverse reactions 
are a subset of all suspected AEs in which there is a reason to conclude that the drug caused 
the event.  
Unexpected Adverse Drug Reaction (UADR): An adverse reaction, the nature or severity 
of which is not consistent with the applicable product information (e. g. Investigator’s 
Brochure for an unapproved investigational medicinal product).  
Serious and Unexpected Suspected Adverse Reaction (SUSAR): A serious UADR.  The 
sponsor must report any suspected SUSAR in an IND safety report (21 CFR 312.32(c)(1)(i)). 
Before  submitting an IND safety report, the sponsor needs to ensure that the event meets all 
three of the definitions:  
• Suspected adverse reaction  
• Serious  
• Unexpected  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 40 of 69 Global Versio n 2.0  
Severity: AEs will be graded on a 3 -point scale and reported as indicated in the CRF. The 
intensity of an AE is defined as follows:  
1 = Mild: event is medically significant but produces no disruption to daily activity  
2 = Moderate: event is medically significant and reduces or affects normal daily activity  
3 = Severe: event is medically significa nt and results in inability to work or perform  
normal daily activity  
Investigational Product Causality: An assignment made by the investigator based on the 
circumstances of the event and its analysis. Cases with causal relationship classified as 
possible, probable , or definite are defined as related. Cases with causal relationship 
categorized as not likely or unrelated are defined as not related. Relationship  of an AE to 
dosing will be assessed as follows:  
• Definite:  The event responds to withdrawal of the i nvestigational product (dechallenge), 
and recurs with rechallenge by administration of the investigational product   
• Probable:  There is a reasonable causal relationship between the investigational product 
and the AE. The event responds to dechallenge. Recha llenge is not required  
• Possible:  There is a reasonable causal relationship between the investigational product 
and the AE. Dechallenge is lacking or dechallenge response is unclear  
• Not Likely : There is a temporal relationship to investigational product adm inistration, 
but there is not a reasonable causal relationship between the investigational product and 
the event  
• Unrelated:  There is not a temporal or causal relationship to investigational product 
administration  
 
6.16.2  Eliciting and Reporting AEs  
After a subje ct consents to participation in the study, the  investigator will periodically assess 
subjects for the occurrence of AEs. To avoid bias in collecting information about AEs, the 
investigator should ask subjects the following question: "How have you felt sinc e you were 
last checked?" All AEs (serious and non -serious) reported by the subject must be recorded in 
the source documents and CRFs.  
It is the investigator's  responsibility to review the results of all laboratory tests as they 
become available. For each abnormal laboratory test result , the investigator needs to ascertain 
if this is a clinically significant change from baseline for that individual subject . This 
determination, however, does not necessarily need to be made the first time an abnormal 
value is  observed. The investigator may repeat the laboratory test or request additional tests 
to verify the results of the original laboratory tests . If the laboratory value is determined to be 
a clinically significant and abnormal change from baseline for that s ubject, this is considered 
a laboratory AE.  
In addition, the sponsor ’s Medical Monitor or its designated personnel must be notified 
immediately by telephone, email, or fax of any immediately reportable AEs (IRAE) 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 41 of 69 Global Versio n 2.0 according to the procedure outlined below. Special attention should be paid to recording 
hospitalization and concomitant medications.  
6.16.3  Immediately Reportable AEs  
The investigator must report any SAE to the sponsor or its representative immediately after 
the investigator becomes aware of the event. An SAE form should be completed and sent to 
the sponsor or its representative  within 24 hours of knowledge of the event.  
Non-serious events that require discontinuation of investigational product (including 
laboratory abnormalities) should be reported to t he sponsor within 3 working days. The CRF 
AE form should be completed as directed by  to the sponsor.  
Subjects experiencing an SAE should be followed clinically until their health has returned to 
baseline status or no further improvement in condition can be  expected with further care. It is 
expected that the investigator will provide or arrange appropriate supportive care for the 
subject.  
6.16.4  Pregnancy   
Women of childbearing potential  (WOCBP ) who are sexually active must use an effective 
method of birth control during the course of the study, in a manner such that risk of failure is 
minimized.  
Before enrolling WOCBP in this clinical trial, investigators must review guidelines about 
study participation for WOCBP. The topics should generally include:  
• General inform ation  
• Informed consent form  
• Pregnancy prevention information  
• Drug interactions with hormonal contraceptives  
• Contraceptives in current use  
• Guidelines for the follow -up of a reported pregnancy  
 
Prior to study enrollment, WOCBP must be advised of the importan ce of avoiding pregnancy 
during trial participation and the potential risk factors for an unintentional pregnancy. The 
subject must sign an informed consent form confirming that  the above -mentioned risk factors 
and that the consequences were discussed with  her. 
During the study, all WOCBP should be instructed to contact the investigator immediately if 
they suspect they might be pregnant (e.g. missed or late menstrual cycle).  
If a subject or investigator suspects that the subject may be pregnant prior to inv estigational 
product administration, the investigational product administration must be withheld until the 
results of serum pregnancy tests are available. If the pregnancy is confirmed, the subject must 
not receive the investigational product and must not be enrolled or remain in the study. If 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 42 of 69 Global Versio n 2.0 pregnancy is suspected while the subject is receiving study treatment, the investigational 
product must be withheld immediately until the result of the pregnancy test is known. If 
pregnancy is confirmed, the investiga tional product will be permanently discontinued and the 
subject will be withdrawn from the trial. Exceptions to study discontinuation may be 
considered for life -threatening conditions only after consultations with a sponsor Medical 
Monitor or designated pe rsonnel. The investigator must notify the Medical Monitor within 3 
working days of any female subject who becomes pregnant. This reporting requirement will 
continue until 4 weeks after the last investigational product exposure.  
The investigator must recor d the event on the Pregnancy Surveillance Form and forward it to 
sponsor’s Medical Monitor.  
Protocol required procedures for study discontinuation and follow -up must be performed on 
the subject unless contraindicated by pregnancy ( e.g. x-ray studies). Othe r appropriate 
pregnancy follow -up procedures should be considered if indicated. In addition, the 
investigator must report to the sponsor, on the appropriate Pregnancy Surveillance Form, 
follow -up information regarding the course of the pregnancy, including  perinatal and 
neonatal outcome. Infants will be followed for a minimum of six months.  
6.16.5  Procedure for Breaking the Blind  
As indicated in Section 5.5  above, the sponsor, medical monitor, study coordinators, 
pharmacists, study su bjects, and the CEC members will be blinded to the treatment 
assignment during the study period. The investigator should also remain blinded to the 
subject treatment during the entire study unless knowledge of the subject’s treatment is 
required for clinic al care and safety. The Emergency Code Break module in the IWRS is 
used for such situations. The investigator must confirm the intention to unblind the subject’s 
treatment to obtain the dose information in IWRS. Upon completion of the unblinding, the 
syste m will send an alert to designated study team members that an unblinding event has 
occurred. Documentation of breaking the blind should be recorded in the subject’s medical 
record with the date and time the blind was broken, and the names of the personnel 
requesting and authorizing unblinding. The treatment assignment will continue to be 
withheld from the CEC members until all phase 3 studies are completed.  
6.16.6  Follow -up of Non -Serious AEs  
Non-serious AEs that are identified on the last scheduled contact must be recorded in the AE 
CRF with the current status noted. All non -serious events that are ongoing at the time will be 
recorded as ongoing in the CRF.  
6.16.7  Follow -up of Post -Study SAEs  
SAEs that are identified on the last scheduled contact must be recorded on th e AE CRF page 
and reported to the sponsor according to the reporting procedures outlined in Section 6.16.2 . 
These may include unresolved previously reported SAEs, or new SAEs. The investigator 
should follow these  SAEs until the events are resolved, or the subject is lost to follow -up. 
Resolution means the subject has returned to the baseline state of health, or the investigator 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 43 of 69 Global Versio n 2.0 does not expect any further improvement or worsening of the subject’s condition. The 
investigator should continue to report any significant follow -up information to the sponsor 
until the event has been resolved.  
Any new SAEs reported by the subject to the investigator that occur after the last scheduled 
contact, and are determined by the in vestigator to be reasonably associated with the use of 
the investigational product, should be reported to the sponsor or designated personnel. This 
may include SAEs that are captured on follow -up telephone contact or at any other time point 
after the defin ed study period (i.e . up to last scheduled contact). The investigator should 
follow SAEs identified after the last scheduled contact until the events are resolved, or the 
subject is lost to follow -up. The investigator should continue to report any signific ant follow -
up information to the sponsor until the event has been resolved. This study requires that 
subjects be actively monitored for SAEs for at least 4 weeks after the last treatment.  
6.16.8  Urinary Tract Infections (UTIs)  
Events potentially representing UTI s, including cystitis, urethritis, pyelonephritis, or 
urosepsis, should be carefully evaluated . Documentation  of signs, symptoms, culture results 
for infectious agent, and treatment should be undertaken when appropriate.  
The investigator should query the subject at every clinical visit for symptoms that may be 
related to a UTI and, if appropriate, document these events as symptomatic UTI in the CRF 
unless an alternative diagnosis is present. In addition, a clean catch urine sample will be 
obtained at all c linical visits and a urinalysis will be performed on that sample at every 
clinical visit. A positive urinalysis will be defined as one with detectable leukocyte esterase 
and/or nitrites. If the subject reports symptoms consistent with a UTI or the urinalys is at the 
clinical site is positive, a urine culture will be performed at the central laboratory. A positive 
urine culture will be defined as one with 105 CFU of any species. The investigator may also 
perform a urine culture using local resources if necess ary for clinical care.  
6.16.9  Genital Mycotic Infections (GMIs)   
The investigator will query the subjects for signs or symptoms that may represent a GMI at 
all clinic visits. GMIs will be diagnosed based on symptoms and, if appropriate, physical 
exam and laborat ory findings. Investigators must exclude the possibility of sexually 
transmitted infections before diagnosing GMI. Diagnosis of GMIs must be documented in 
the CRF.  
6.16.10  Hepatotoxicity  
If plasma AST and/or ALT concentrations > 3 x ULN are detected, the investig ator will 
record in the source documents : 
• the date corresponding to the date of the laboratory abnormality  
• the type, frequency, and dose of any concurrent medications or supplements taken by the 
subject within the 14 days of the detected abnormality  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 44 of 69 Global Versio n 2.0 • any sy mptoms or change in physical exam that have occurred since the prior assessment  
 
The investigator should perform additional laboratory and imaging tests to attempt to 
establish the cause of the AST and ALT elevations, including ruling out any potential 
contribution from bone or muscle etiologies.  
Any clinically significant increase in hepatic enzymes and specifically any ALT or AST > 3 
x ULN requires immediate repeat test within 48 to 72 hours  to confirm the hepatic enzyme 
elevation . Testing  should be repea ted based on the clinical situation at least every 96 hour s (4 
days) until ALT and AST return to < 2.5 x ULN  or until the liver function test results are 
stable and significant changes are not expected anymore . Study medication should be 
stopped and the ev ent should be reported as a laboratory AE within the CRF if the enzyme 
elevation is confirmed or worsening.  
Should it be determined that the etiology is an unrelated acute or chronic medical condition 
(e.g.; NASH, Hepatitis A) and the return of LFT abnorm alities to normal is unlikely  during 
the course of the illness, further testing and follow up is at the investigator ’s discretion.  
Hepatotoxicity will be diagnosed and entered as an AE should any of the following occur:  
• ALT or AST > 8 x ULN  
• ALT or AST > 3 x ULN and total bilirubin > 2 x ULN or INR > 1.5  
• ALT or AST > 3 x ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5 %) 
 
In the event of hepatotoxicity, investigational produc t should be permanently discontinued. 
The investigator is encouraged to consult with the Medical Monitor regarding diagnostic 
evaluation for the hepatic enzyme elevations. Consultation with a hepatologist may also be 
appropriate in some circumstances.  
6.16.11  Hypo glycemia  
Events of hypoglycemia or potentially representing hypoglycemia should be carefully 
evaluated.  
All subjects will be provided with a glucometer  for recording blood glucose measurements  
and a diary to record signs and symptoms of hypoglycemia. Dur ing the study the subject is 
expected to record daily SMBG readings and all signs and symptoms that may potentially 
reflect hypoglycemia. In the event of such signs or symptoms, the subject is expected to 
check the blood glucose if it is reasonably safe to  do so, and , if appropriate,  consume 
carbohydrates to treat hypoglycemia.  
The subject will be expected to record the following information for each hypoglycemic 
event  in the glycemic control diary : 
• Signs and symptoms attributed to hypoglycemia and the tim e and date on which they 
occurred  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 45 of 69 Global Versio n 2.0 • SMBG reading at the time of the signs and symptoms attributed to hypoglycemia  
• Time elapsed from the most recent meal to the onset of signs and symptoms  
• Duration, intensity, and type of any exercise within the 24 h prior t o the signs and 
symptoms  
• Type of treatment used (e.g., juice, crackers) for the signs and symptoms and whether 
assistance was required from another person to administer the treatment  
• SMBG reading 15 minutes after treatment with carbohydrate and the time at  which this 
was measured  
• Whether or not the signs and symptoms attributed to hypoglycemia resolved after blood 
glucose returned to normal  
 
Subjects are encouraged to call the study clinic should signs and symptoms potentially 
related to hypoglycemia occur.  
At each study visit, the investigator is expected to review the glucometer and glycemic 
control diary with particular attention to any SMBG value < 70 mg/dL and any recorded 
signs or symptoms potentially related to hypoglycemia. In addition, the investiga tor should 
query the subject with regard to the occurrence of signs and symptoms potentially related to 
hypoglycemia even if none are recorded in the diary.  
In the event of a blood glucose value < 70 mg/dL or signs and symptoms potentially related 
to hypo glycemia, the investigator should complete the supplemental CRF which will include 
data from the glycemic control diary and action items to reduce future hypoglycemia 
episodes.  
Hypoglycemia events will be recorded in the hypoglycemia log under 5 categorie s: 
1. Severe hypoglycemia: an event requiring assistance by another person to actively 
administer carbohydrate, glucagon, or other resuscitative actions. These episodes may be 
associated with sufficient neuroglycopenia to induce seizure or coma. Plasma glucos e 
measurements may not be available during such an event, but neurological recovery 
attributable to the restoration of plasma glucose to normal is considered sufficient 
evidence that the event was induced by a low plasma glucose concentration. All such 
events should be recorded as SAEs in the CRF  
2. Documented symptomatic hypoglycemia: an event during which typical symptoms of 
hypoglycemia are accompanied by a measured plasma glucose concentration < 70 mg/dL 
(3.9 mmol/L ) 
3. Asymptomatic hypoglycemia: an event not  accompanied by typical symptoms of 
hypoglycemia but with a measured blood glucose concentration  < 70 mg/dL (3.9  
mmol/L ) 
4. Probable symptomatic hypoglycemia: an event during which symptoms of hypoglycemia 
are not accompanied by a blood glucose determination but that is presumably caused by a 
blood glucose concentration < 70 mg/dL (3.9 mmol/L ) 
5. Relative hypoglycemia: An event during which the person with diabetes reports any of 
the typical symptoms of hypoglycemia, and interprets those as indicative of 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 46 of 69 Global Versio n 2.0 hypoglyc emia, but with a measured plasma glucose concentration ≥ 70 mg/dL 
(3.9 mmol/L).  
 
While each event meeting the criteria above will be entered into the hypoglycemia log, only 
critical hypoglycemia, documented symptomatic hypoglycemia, asymptomatic 
hypoglycemia, and probable hypoglycemia will be entered as AEs.  
In the event of asymptomatic hypoglycemia, the investigator should review the signs and 
symptoms of hypoglycemia with the subject to elicit a complete description and should 
review proper glucometer technique to ensure that the low glucose value is not due  to 
improper use of the glucometer.  
The investigator should be alerted to the likelihood of improper glucose measurement 
technique if a study subject reports an SMBG value < 55 mg/dL that is not associated with 
any signs or symptoms of hypoglycemia and is not treated by some form of glucose 
administration.  
In the event of probable symptomatic hypoglycemia, the investigator should encourage the 
subject to obtain glucose values, when possible, in the context of signs and symptoms of 
hypoglycemia, even if the  glucose value is measured after treatment for the symptoms is 
administered.  
If hypoglycemia occurs in any subject prescribed rescue medication for hyperglycemia 
during the study, the total daily dose of the rescue medication should be reduced 50% or 
more at the discretion of the investigator.  
6.16.12  Major Adverse Cardiovascular Event (MACE)  
Evaluation of MACE will be undertaken across the development program for bexagliflozin. 
All MACE reports should also be captured as SAEs and every effort will be made to ensu re 
that events recorded as MACE are coded in a similar manner within the safety database. The 
SAE listing will also be reviewed periodically by the CEC members to identify potential 
MACE that may not have been reported by the site investigators. All subjec ts will be 
followed by investigators for MACE for the duration of the study even if study medication 
has been permanently withdrawn.  
The independent CEC will receive and adjudicate the following events.  
 All deaths  
 Suspected non -fatal MI  
 Suspected hospital ization for unstable angina (HUA)  
 Suspected TIA and stroke  
 Suspected hospitalization for heart failure (HF)  
 Reported coronary revascularization procedure  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 47 of 69 Global Versio n 2.0 6.16.13  Diabetic Ketoacidosis (DKA)  
DKA is a serious, acute complication of diabetes and can be life -threate ning. Subjects will be 
educated on the signs and symptoms of DKA and are required to call the study clinic and 
seek treatment should such signs and symptoms occur.  
During the clinical trial period, potential DKA will be monitored by the routine measuremen t 
of urinary ketones and assessment for signs or symptoms of acidosis at every clinic visit. 
Clinical presentations, such as difficulty breathing, abdominal pain, nausea, vomiting, 
lethargy, a fruity smell in the breath, or laboratory values that suggest c linically -significant 
acidosis should be documented. Treatment  of DKA should be provided when appropriate.  
If ongoing symptoms or signs suggest a possible DKA, the investigator should perform 
relevant laboratory testing while directing appropriate medical  care for the subject. If DKA is 
suspected, regardless of the blood glucose level, the following assessments should be done 
immediately: physical exam and serum glucose, bicarbonate, electrolytes, and serum ketones . 
Laboratory values should be  measured STA T at a local laboratory. If ketoacidosis is likely, 
investigational product administration should be discontinued and immediate appropriate 
medical therapy, including insulin, should be initiated. A glucose infusion may be provided if 
necessary to avoid hy poglycemia during insulin therapy. Insulin treatment should continue 
until resolution of the ketoacidosis and stabilization of the subject’s clinical condition. 
Investigational product administration may be resumed following stabilization of the 
subject’s condition.   The investigator  should collect the data necessary for the completion of 
the DKA CRF.  
If symptoms suggestive of DKA may have occurred but are not ongoing, investigator should 
review available data in order to complete the DKA CRF. The investig ator may also perform 
laboratory assessment using local resources if necessary for clinical care.  
6.16.14  Amputation  
Amputation and related AEs will be recorded in a dedicated CRF . During each study visit, 
the investigator should query the subject for any amputat ion and related AEs and procedures. 
Investigators are reminded to counsel appropriate foot care to avoid cuts or sores and to treat 
even minor cuts or sores  to prevent infection and ulceration. Patients who  have had a 
previous amputation  should be closely  monitored.  Subjects with history of amputation, or 
risk factors for amputation should be counseled to seek preventive care to prevent further 
complications. Such risk factors include peripheral vascular disease and diabetic neuropathy.  
Special attention ma y be appropriate for patients who are also receiving thiazide diuretics as 
these have been shown to increase the risk of amputation in diabetics.   
6.16.15  Pancreatitis  
Subjects should be informed that persistent severe abdominal pain, sometimes radiating to 
the ba ck or accompanied by vomiting, is the symptom of acute pancreatitis. Subjects must 
contact the clinic immediately if they experience  these symptoms. The investigator  should 
observe carefully for signs  and symptoms of pancreatitis. Laboratory testing , inclu ding 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 48 of 69 Global Versio n 2.0 amylase and lipase , should be performed  using local resources if necessary for diagnosis and 
clinical care. If pancreatitis is suspected, administration of study products should be 
discontinued promptly and appropriate m anagement should be initiated. Diagnosis of 
pancreatitis must be documented in the CRF.  
6.17 Concomitant Medication Assessments  
A concomitant medication is any medication that the subject has been taking prior to 
enrollment and that the subject is expected to continue to take for some porti on of the trial, as 
well as any medication other than the investigational product that the subject takes during the 
course of the trial. Changes in dose and/or frequency from therapies taken prior to 
randomization and their rationale must be recorded in th e CRF.  
The medications or treatment for controlling hyperglycemia  must be recorded as concomitant 
medications in the CRF. Any medication given to treat hyperglycemia and continued for 
more than 2 weeks is considered a rescue therapy and should be recorded in the concomitant 
medication log.  
All prescription and over -the-counter medications, including vitamins and herbal 
supplements, that subjects receive during the trial must be documented on the CRF. This 
documentation should continue until the subjects com plete the study.  
Concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHO -DD). A table of concomitant medications based on the anatomic 
therapeutic chemical classification (ATC) and preferred name will be produced. A listing of 
concomitant medications will include all medications taken by any subjects during the course 
of the study.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 49 of 69 Global Versio n 2.0 7 STUDY ACTIVITIES  
The study activities at each clinic visit listed below are presented in Appendix 1 . The 
required laboratory tests scheduled at each visit are listed in Appendix 2 . Detailed study 
procedures are described in Section 6 .  
A visit window of ± 3 days is allowed for all visits excep t visit V3. Visit 3 is the day of 
randomization and the basis for the visit window.  
7.1 V1/ Screening  
• Explain the content of the informed consent materials to the subject and collect signed 
informed consent  
• Collect needed information and evaluate conformance  to inclusion and exclusion criteria  
• Obtain Medical History and Demographic Information  
• Perform an abbreviated physical examination  
• Measure vital signs, including BPs and heart rate  
• Measure weight  
• Perform a 12 -lead ECG measurement  
• Draw blood if an approxim ately  10-h fast has been completed by the subject as described 
in section _Sample_Collection,_Storage, 6.10.2 .  The specific laboratory tests scheduled 
for this visit are listed  in Appendix 2  
• Collect a clean -catch, mid -stream urine sample  
 
7.2 V2/ Run In  
• Counsel subject on appropriate diet and exercise  
• Dispense glucometer and instruct subject in SMBG determination and recording  
• Dispense two run -in kits for run -in period  
• Assess AEs 
• Record concomitant medic ations  
 
7.3 V3/ Randomization  
• Collect needed information and evaluate conformance to inclusion and exclusion criteria  
• Perform a complete physical examination  
• Measure vital signs, including BPs and heart rate  
• Measure weight  
• Perform a 12 -lead ECG measurement  
• Draw blood if an approximately 10  h fast has been completed by the subject as described 
in section 6.10.2 .  The specific laboratory tests scheduled for this visit are listed  in 
Appendix 2  
• Collect a clean -catch, mid -stream urine sample  
• Review SMBG and glycemic control record  
• Record drug accountability, collect run -in product bottle s 
• Dispense investigational product based on rando mization  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 50 of 69 Global Versio n 2.0 • Assess AEs 
• Record concomitant medications  
 
7.4 V4/ 6 weeks  
• Measure vital signs, including BPs and heart rate  
• Measure weight  
• Draw blood if an approximately 10 -h fast has been completed by the subject as described 
in section 6.10.2 .  The specific laboratory tests scheduled for this visit are listed  in 
Appendix 2  
• Collect a clean -catch, mid -stream urine sample  
• Review SMBG an d glycemic control record  
• Record drug accountability  
• Assess AEs  
• Record concomitant medications  
 
7.5 V5/ 12 weeks  
• Measure vital signs, including BPs and heart rate  
• Measure weight  
• Draw blood if an approximately 10 -h fast has been completed by the subject as de scribed 
in section 6.10.2 .  The specific laboratory tests scheduled for this visit are listed  in 
Appendix 2  
• Collect a clean -catch, mid -stream urine sample  
• Review SMBG and glycemic control record  
• Record drug accountability  and collect previous investigational product bottle s 
• Dispense investigational product based on randomization  
• Assess AEs  
• Record concomitant medications  
 
7.6 V6/ 18 weeks  
• Measure vital signs, including BPs and heart rate  
• Measure weight  
• Draw blood if an approximately 10 -h fast has been completed by the subject as described 
in section 6.10.2 .  The specific laborat ory tests scheduled for this visit are listed  in 
Appendix 2  
• Collect a clean -catch, mid -stream urine sample  
• Review SMBG and glycemic control record  
• Record drug accountability  
• Assess AEs  
• Record concomitant medications  
 
7.7 V7/ En d of Treatment  
• Perform an abbreviated physical examination  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 51 of 69 Global Versio n 2.0 • Measure vital signs, including BPs and heart rate  
• Measure weight  
• Perform a 12 -lead ECG measurement  
• Draw blood if an approximately 10 -h fast has been completed by the subject as described 
in sectio n 6.10.2 .  The specific laboratory tests scheduled for this visit are listed  in 
Appendix 2  
• Collect a clean -catch, mid -strea m urine sample  
• Review SMBG and glycemic control record  
• Record drug accountability  and collect previous investigational product bottle s 
• Assess AEs  
• Record concomitant medications  
 
7.8 V8/ Follow up  
• Perform a complete physical examination  
• Measure vital signs, in cluding BPs and heart rate  
• Measure weight  
• Perform a 12 -lead ECG measurement  
• Draw blood if an approximately 10 -h fast has been completed by the subject as described 
in section 6.10.2 .  The specific laboratory tests scheduled for this visit are listed  in 
Appendix 2  
• Collect a clean -catch, mid -stream urine sample  
• Review SMBG and glycemic control record  
• Assess AEs  
• Record concomita nt medications  
 
7.9 Early Termination Procedures  
Subjects who withdraw consent and have received investigational product s should  have a 
follow -up examination, including a complete physical examination, vital signs, ECG, and 
clinical laboratory tests (hematolog y, serum chemistry, and glycemic control). The sponsor 
must be notified in the event that a subject withdraws or has been withdrawn from the study.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 52 of 69 Global Versio n 2.0 8 QUALITY CONTROL AND ASSURANCE  
The clinical research facility will be monitored by the study monitor to ensur e correct 
performance of the study procedures and  to ensure that the study is conducted according to 
the protocol and rel evant regulatory requirements. CRF entries will be verified with the 
source documentation.  
Quality control principles will be applied t hroughout the performance of this study by 
following the Standard Operating Procedures ( SOPs) of the contract research organization 
(CRO ) and the sponsor. Review procedures will be implemented at the CRO for all 
documents that are gene rated in relation to the study.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 53 of 69 Global Versio n 2.0 9 PLANNED STATISTICAL  METHODS  
9.1 General Considerations  
The following sections provide a summary of the planned analysis of the trial but a complete 
statistical analysis plan will be developed as a separate document and will be the final plan. 
All st atistical analyses will be performed using SAS Version 9.2 or higher.  
In general, descriptive statistics (number of subjects [N], mean, standard deviation [SD], Q1, 
median, Q3, minimum and maximum) will be presented for continuous variables, and 
frequency and percentage for categorical variables.  
The primary efficacy non -inferiority test will be one -sided at 0.025 significance level. The 
upper bound of the 95% confidence interval (CI) on the difference of HbA1c reduction 
between bexagliflozin and sitaglipt in will be used to determine the study’s conclusion. That 
is, if the upper bound of the CI is within 0.35%, then the primary objective of the study is 
met.  Superiority will be declared without additional statistical testing when the upper bound 
of the 95% CI for the difference in change from baseline at week 24  in HbA1c comparing 
bexagliflozin group with sitagliptin  group is less than 0.  
The secondary efficacy objectives will be tested at two -sided 0.05 significance level 
following a sequential testing pro cedure to control the overall type I error of 0.05. The 
secondary efficacy endpoints will be tested only if the primary efficacy assessment achieves 
significance, and following the hierarchy as below:  
1. Superiority test of the change in FPG in the bexagliflo zin group vs. the sitagliptin group 
at week 24  
2. Superiority test of the change in body weight in subjects with baseline BMI ≥ 25 kg/m2 in 
the bexagliflozin group vs. the  sitagliptin group at week 24  
3. Superiority test of the change in SBP in the bexagliflozin group vs. the sitagliptin group 
at week 24  
 
The exploratory efficacy objectives and safety objectives will be analyzed descriptively.  
9.2 Determination of Sample Size  
Approximate total 374 subjects will be randomized and equally allocated to receive 
bexagliflozin tablets (20 mg) + sitagliptin tablets (pl acebo), or bexagliflozin tablets (placebo) 
+ sitagliptin tablets (100 mg)  
The sample size calculation for this study is based on a two group t -test with a one -sided 
significance at the 0.025 level and the following assumptions:  
1. The non -inferiority limit (m argin) for mean change from baseline to week 24  in HbA1c 
comparing bexagliflozin group to sitagliptin  group will be 0.35%  
2. The pooled SD for the change from baseline to week 24  in HbA1c for bexagliflozin 
group and sitagliptin  group will be 1.0%  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 54 of 69 Global Versio n 2.0  
Under the a bove assumptions, an estimated sample size of 172  patients is needed in each 
treatmen t arm to detect non -inferiority of bexagliflozin to sitagliptin  with respect to change 
in HbA1c at week 24  from baseline . This estimation is based on a one -sided t -test wi th 90% 
power at a 0.025 level of significance. A sample size of 187 per arm has been selected to 
account for approximate 8% drop -out rate and to allow adequate safety evaluation. The total 
sample size for this study will be 374 subjects.  
This study will be  conducted at multiple investigative sites and will likely involve various 
numbers of subjects at each site. Enrollment will be on a competitive basis, but  will be 
capped at 30 subjects from each site.  
9.3 Analysis Populations  
9.3.1  Intention -to-Treat Analysis Set 
All subjects who are randomized regardless of treatment adherence or availability of follow -
up data will be included in the intention -to-treat analysis set (ITT). All analyses of the ITT 
will be based on each subject’s randomized assigned treatment. The IT T analysis set will 
serve as the primary set for the efficacy analyses.  
9.3.2  Safety Analysis Set  
All subjects who are randomized and take at least one dose of double -blind study medication 
will be included in the Safety Analysis Set. Safety analyses will be bas ed on the medication 
that was actually taken by each subject.  The Safety Analysis Set  is the primary analysis set 
for safety  evaluation . 
9.3.3  Per Protocol Analysis Set  
The Per Protocol (PP) Analysis Set will include all subjects in the ITT who meet the study 
eligibility requirements and have no major protocol deviations that affect the validity of the 
efficacy measurements. Protocol deviations that may result in subject exclusion from the PP 
Analysis Set will be detailed in the Statistical Analysis Plan. The su bject assignment to the 
PP analysis set will be determined prior to database lock. The PP analysis set will serve as 
the secondary set for efficacy assessments.  
9.4 Demographics and Baseline Characteristics  
Demographic and  baseline characteristics will be summ arized descriptively based on the ITT 
and PP analysis set for each treatment group as well as for all subjects combined. Key 
variables include age, gender, race, ethnicity, baseline HbA1c values, BP, body weight, BMI,  
FPG level, eGFR, duration of diabetes and prior anti -diabetic treatment status at screening 
(including type of therapy used [metformin, SU, DPP -4 inhibitor, alpha -glucosidase inhibitor 
etc.). In general, baseline measurement is defined as the last measurement prior to the first 
dose of double -blind medication. 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 55 of 69 Global Versio n 2.0 9.4.1  Concomitant Medications  
Concomitant medications will be coded using the World Health Organization Drug 
Dictionary (WHO -DD), and include medications that are either started prior to the study 
treatment and continue to be taken during the study treatment period, or medications started 
after the start of study treatment. Concomitant medications will be summarized by ATC term 
and by treatment groups.  
9.5 Primary Efficacy Analyses  
9.5.1  Hypotheses for the Primary Endpoint  
The null and alternative hypoth eses for the primary endpoint are:  
H0: µ bexagliflozin  - µ comparator  > δ 
Ha: µ bexagliflozin  - µ comparator  ≤ δ 
Where µ bexagliflozin  and  µ comparator  represent the mean change in HbA1c at week 24  from 
baseline for bexagliflozin and comparator groups, respectively. Non -inferiority margin δ is 
chosen to be 0.35% using clini cal judgment, with reference to relevant regulatory guidance.  
9.5.2  Statistical Methods for Primary Analyses  
For the primary endpoint , the treatment difference will be examined by using a mixed model 
repeated measures (MMRM) analysis of covariance model (ANCOVA) . The model will 
include  treatment, visit, treatment -by-visit interaction , region  and the baseline HbA1c value 
as a fixed effect covariate. Least squares mean treatment differences between the 
bexagliflozin group and the comparator group at week 24  will be  estimated from the model. 
An unstructured covariance will be used to model the within -subject correlation. If the model 
with the unstructured covariance structure does not converge, an autoregressive(1) 
covariance structure will be used.  
HbA1c values obt ained after the start of rescue medication will not be excluded in the 
analysis. These analyses will be conducted on both ITT (primary) and PP analysis sets, and 
conclusions can be considered more robust when both approaches support the non -inferiority 
of the treatment.  
In non -inferiority analysis, a CI is calculated to estimate the range of values in which the  
treatment difference  is likely to lie.  This CI is used to provide the basis for drawing the 
study’s conclusions.  In this specific test, if the 95% C I lies below the specified non -
inferiority margin 0.35 %, the results would lead to a conclusion of  non-inferiority  of 
bexagliflozin treatment to sitagliptin  treatment.  Superiority of bexagliflozin group over 
sitagliptin  group at week 24  in HbA1c change fro m baseline will be declared if the upper 
bound  of 95% CI is less than 0.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 56 of 69 Global Versio n 2.0 Sensitivity analyses will also be performed as the following, and these analyses will be 
conducted for ITT and PP analysis sets.  
1. Missing data will be imputed via multiple imputations , following which the MMRM will 
be repeated on the complete datasets with results combined across complete datasets 
using standard MI techniques; HbA1c values collected after the start of rescue medication 
will not be excluded.  
1. Missing data will be imputed  via LOCF, following which the MMRM will be repeated; 
HbA1c values collected after the start of rescue medication will be considered missing.  
2. HbA1c values collected after the start of rescue medication will be considered missing, 
and the MMRM analyses will  be re -performed.  
 
9.5.3  Analysis of  Dropouts Pattern  
The early termination rate is estimated to be 8%. To the extent possible, attempts will be 
made to minimize the amount of missing data through measures planned in the study 
conduct.  
The number, timing, patter n, reason for and possible implications of missing values in 
efficacy assessments will be investigated. The dropout patterns will be assessed by Kaplan -
Meier plots if applicable to assess whether they differ between treatment groups.  
9.6 Secondary Efficacy Ana lyses  
To assess the treatment effect on the change in FPG in the bexagliflozin group vs. the 
sitagliptin group at week 24 , similar to the primary endpoint analysis method, MMRM 
ANCOVA  will be implemented (values obtained after the start of rescue medicatio n will not 
be excluded in the analysis) . The model will include  treatment , visit,  treatment -by-visit 
interaction, region and the baseline FPG value as fixed effects/covariates. Least squares mean 
treatment differences between the bexagliflozin group and th e comparator group will be 
estimated from the model. The corresponding 95% CI and p -value will be provided.  
The change in body weight for subjects with baseline BMI ≥ 25 kg/m2 in the bexagliflozin 
group vs. the sitagliptin group at week 24, and the change in SBP in the bexagliflozin group 
compared with sitagliptin  group at week 24  will be analyzed using the same method.  
All analyses will be conducted in ITT analysis set. A hierarchical testing procedure will be 
applied to above three endpoints in the sequen ce provided in Section 9.1. 
9.7 Other Efficacy Analyses  
Changes in HbA1c, FPG, SBP, and body weight for all subjects during the treatment period 
will be summarized descriptively by each time point (i.e., Weeks 6, 12,  18, 24, …, etc .). In 
addition, these endpoints may be analyzed using a similar MMRM model as used for the 
primary analysis of HbA1c to compare two treatment groups  at different time points .  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 57 of 69 Global Versio n 2.0 Cumulative summary on the proportion of subjects  achieving  HbA1c  < 7% will be p resented 
over time. Generalized estimation equation (GEE) logistic regression method may be utilized 
for assessment of treatment effects.  
Analyses will be conducted using ITT analysis set.  
9.8 Analysis of Safety  
Safety data include AEs, physical exam results, vital signs, ECG results, and clinical lab 
results including serum chemistry, hematology, serum lipids, glycemic control parameters 
and urinalysis. Observed data will be summarized by treatment using safety analysis set.  
9.8.1  Adverse Events  
AEs will be mapped to preferred term and body system using the Medical Dictionary for 
Regulatory Activities (MedDRA) dictionary. AEs that begin at or after the first 
administration of double -blind study medication or existing AEs that worsen in severity after 
the first dose of double -blind study medication are considered treatment emergent AEs 
(TEAE). The number and percentage of subjects reporting TEAEs will be summarized for 
each treatment group by MedDRA system organ class and preferred term. Further summaries 
by severity  and by relationship to study treatment will also be provided. Drug -related AE will 
be considered those to be at least possibly related to the study treatments based on the 
investigators assessment.  
The number and percentage of subjects reporting serious A Es, and the number and 
percentage of subjects reporting AEs leading to treatment discontinuation will also be 
summarized for each treatment group by MedDRA system organ class and preferred term.  
9.8.2  Adverse Event s of Interest  
AE of interest include UTI, GMI, d iuretic effects, hypotension episodes, hypoglycemia, 
hepatotoxicity, MACE , falls and  fracture s, malignancy, hypersensitivity reactions, 
pancreatitis, amputations  and renal failure events. These AEs of interest  except DKA, MACE  
and amputations will be prosp ectively identified based on the MedDRA preferred terms in 
the AE log by a medical expert prior to the data base lock and unblinding of the individual 
subject treatment assignment. The list of AE of interest will be confirmed in a peer review 
process. DKA and MACE will be identified by the investigator and documented in the CRF , 
and subsequently adjudicated by seperate  independent committee s. Adjudicated results will 
be used for summary.   Amputation events will be recorded in the procedures and amputation 
CRF.   
The number and percentage of subjects experienced TEAE of  interest will be summarized 
for each treatment group by types of events. The incidence rate of AE of interest per 100 
patient years will also be summarized. Additional analyses will be specif ied in the statistical 
analysis plan to evaluate other event associated safety parameters and potential risks in 
subpopulations based on age, gender, or other baseline characteristics . 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 58 of 69 Global Versio n 2.0 9.8.3  Clinical and Laboratory Events and Analyses  
Clinical laboratory (see Section 6  for a complete list), vital signs, and 12 -lead ECG will be 
measured at scheduled visits (see Appendix 1 ). These data will be summarized as actual 
values and changes from baseline b y treatment for each visit for selected parameters.  
Laboratory data will be classified as low, normal or high relative to the parameter’s reference 
range. Laboratory abnormalities for each treatment will also be summarized with shift tables 
for selected p arameters.  
9.8.4  Physical Examination  
Physical examination findings will be presented in a by subject listing.  
9.9 Interim Analysis  
No interim analysis will be performed during this study.  
9.10 Final Analysis  
After all subjects have completed the planned 24 weeks of bli nded study treatment and the 
subsequent follow -up visit, the final analysis of the clinical study will be completed. At this 
time, the database will be cleaned and locked, and the treatment codes will be unblinded.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 59 of 69 Global Versio n 2.0 10 ADMINISTRATIVE CONSI DERATIONS  
10.1 Investigato rs and Study Administrative Structure  
Information regarding key personnel involved in the conduct of the study, including names 
and contact details of participating investigators, monitors, clinical laboratories, and technical 
departments and/or institutio ns, as well as information on members of additional study 
committees, will be found in the study files of the investigational site.  
The clinical investigator must personally conduct or supervise the procedures that are 
required in the protocol.  Procedures  that require clinical or medical knowledge must be 
performed by the investigators or qualified sub -investigators.   The investigator may delegate 
tasks to any individual to whom a task is delegated is qualified by education, training, and 
experience (and local licensure where relevant). The investigator must maintain a list of the 
appropriately qualified persons to whom significant trial -related duties have been delegated. 
This list should also describe the delegated tasks and maintain records of  the trai ning that 
individuals have received that qualifies them to perform delegated tasks (e.g., individual’s 
CV, certifications), and identify the dates of involvement in the study.  No study -related 
procedures should be conducted unless the delegated individual  has adequate training on the 
protocol and assigned task  
10.2 Institutional Review Board  (IRB) or Independent Ethics Committee 
(IEC) Approval  
The study protocol, informed consent document, relevant supporting information, and all 
types of subject recruitment or  advertisement information must be submitted to the 
independent review board (IRB) or independent ethics committee (IEC)  for review and must 
be approved by the sponsor and the IRB/IEC before the study is initiated . Any amendments 
or addenda to the protocol  must also be approved by the IRB/IEC prior to implementing 
changes in the study . The investigator is responsible for keeping the IRB/IEC informed of the 
progress of the study and of any changes made to the protocol as deemed appropriate, but in 
any case a t least once a year . The investigator must also keep the IRB/IEC informed of any 
SAEs occurring to subjects under their supervision.  
10.3 Ethical Conduct of the Study  
The procedures set out in this protocol pertaining to the conduct, evaluation, and 
documentati on of this study are designed to ensure that the sponsor and investigator follow 
ICH GCP guidelines (E6) and the guiding principles detailed in the Declaration of Helsinki. 
The study will also be carried out in keeping with applicable local laws and regula tions . An 
inspection by the sponsor representatives and/or their designee and/or other authorized 
regulatory authorities representatives may occur at any time . The investigator must agree to 
the inspection of study -related records by the regulatory authori ty/sponsor representatives, 
and must allow direct access to source documents to the regulatory authority/sponsor 
representatives.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 60 of 69 Global Versio n 2.0 The investigator is responsible for complying with the protocol and all appropriate 
regulations and guidelines governing globa l clinical research . Additionally, he/she is 
responsible for ensuring that all participating staff members are adequately trained and 
competent to perform his/her assigned tasks.  
Modifications to the study protocol will not be implemented by either the spo nsor or the 
investigator without agreement by both parties . However, the investigator may implement a 
deviation from or a change of the protocol to eliminate any immediate hazards to the trial 
subjects without prior IRB/IEC or sponsor approval/favorable op inion . As soon as possible, 
the implemented deviation or change, the reasons for it, and if appropriate, the proposed 
protocol amendment should be submitted to the IRB/IEC  and sponsor.  
Any deviations from the protocol must be fully explained and documented  by the 
investigator. The circumstances, action taken, and impact of the deviation on the trial must be 
communicated by the principal investigator to the designated medical monitor . Any 
subsequent actions will be assessed by the designated medical monitor and documented.  
10.4 Subject Information and Consent  
Prior to the beginning of the study, the investigator must have received from the IEC or IRB 
the written approval or favorable opinion of the informed -consent form and any other written 
information to be prov ided to subjects . The written approval of the IRB/IEC together with 
the approved subject information/informed consent forms must be filed . The informed 
consent form must contain all elements required by authorized regulatory authorities and the 
ICH GCP gui delines (E6), in addition to any other elements required by local regulations or 
institutional policy.  
Written informed consent must be obtained before any study -specific procedure takes place . 
Participation in the study and date of informed consent given by the subject should be 
documented appropriately in the subject’s files . A copy of the signed informed consent form 
must be provided to the subject . If applicable, it will be provided in a certified translation in 
the language understood by the subject, i f not English . Signed consent forms must remain in 
each subject’s study file and must be available for verification by study monitors at any time.  
10.5 Subject Confidentiality  
The information obtained during the conduct of this clinical study is confidential, a nd 
disclosure to third parties other than those noted below is prohibited . Information obtained 
during the conduct of this study will be used by the sponsor in connection with the 
development of the investigational product . The study investigator is oblige d to provide the 
sponsor with complete test results and all data developed in this study . Subject -specific 
information may be provided to other appropriate medical personnel only with the subject’s 
permission . To ensure compliance with current ICH guidelin es, data generated by this study 
must be available for inspection upon request by representatives of national and local health 
authorities, the sponsor, and the IRB/IEC for each study site . Study information from this 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 61 of 69 Global Versio n 2.0 protocol will be posted on clinicaltri als.gov and any local regulatory registry websites, as 
required by regulation.  
Subject names and other identifiers, such as photographs, audio, or videotapes, may not be 
disclosed in any publication without prior written authorization from the subject.  
10.6 Study Monitoring  
An authorized sponsor representative will conduct site visits to inspect study data, subjects’ 
medical records, and CRFs in accordance with ICH guidelines, GCP, and the respective 
national and local government regulations and guidelines.  
The investigator will permit authorized representatives of the sponsor and the respective 
national or local health authorities, other authorized regulatory authorities, and IRB/IEC to 
inspect facilities and records relevant to this study.  
10.7 Case Report Forms and  Study Records  
For each subject consented, a CRF , in paper or electronic format, will be supplied and 
maintained by the CRO staff and signed by the investigator or authorized designee to indicate 
that he/she has reviewed and agrees with the entered data . This also applies to those subjects 
who fail to complete the trial. The reason a subject is withdrawn must be recorded in the 
CRF . 
Entries made in the CRF must be verifiable against source documents. Source documents are 
defined as all medical records, medi cal notes, laboratory results, ECG traces , and any 
additional document other than the CRF that has original subject information contained 
within it.  
All CRFs and source documents should be completed following GCP and the sponsor or its 
designee’s  SOPs.  
10.8 Data Monitoring Committee  
An independent DSMB  will monitor overall safety information during the bexagliflozin  
development program . The safety review activity and potential risk benefit assessments 
utilized by the DSMB will be defined in its charter.  
10.9 Protocol  Violations/Deviations  
Protocol violations include deviations from the inclusion and exclusion criteria, concomitant 
medication restrictions, and any other protoc ol requirement that results in a significant added 
risk to the patient or has an impact on the quality of the data collected or the outcome of the 
study. A deviation occurs when there is non -adherence to study procedures or schedules, as 
specified by the p rotocol, which does not involve inclusion/exclusion criteria or the primary 
endpoint and which does not place the patient at any added risk or affect the data quality or 
study outcome. Examples of deviations may include common out -of-window visits, a misse d 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 62 of 69 Global Versio n 2.0 procedure, etc. Protocol violations will reported in the final clinical study report, whereas 
protocol deviations may be mentioned but are not required to be reported.  
It is important to conduct the study according to the protocol . Protocol deviation  waivers will 
not be prospectively granted by the sponsor . If minor protocol deviations occur, the 
investigator must decide the most appropriate way to proceed with study activities and 
should consult the study representative for assistance. If major protocol deviations occur, the 
sponsor’s Medical M onitor must be notified immediately so that a decision about whether to 
keep the subject in the study can be made.  
Only when an emergency occurs that requires a departure from the protocol for an individual 
subject can there be a departure without the sponsor’s pre -approval . The nature and reasons 
for the protocol deviation /violations  will be recorded in the subject’s CRF, and the principal 
investigator must notify the sponsor . 
Protocol deviations/violations  must be reported in the final study report.  
10.10  Access to Source Documentation  
Authorized sponsor representatives will conduct site visits to inspect study data, subjects’ 
medical records, and CRFs in accordance with ICH guidelines, GCPs, and the respective 
local and national government regulations and guidelines.  
The investigator will permit authorized representatives of the sponsor and the respective 
national or local health authorities, other authorized regulatory authorities, and IRB/IEC to 
inspect facilities and r ecords relevant to this study.  
Each center will be visited at regular intervals by a monitor to ensure compliance with the 
study protocol, GCP, and legal aspects . This will include on -site checking of the CRFs for 
completeness and clarity, cross -checking w ith source documents, and clarification of 
administrative matters.  
All CRF data will be entered into a clinical database . Following the correction of any errors, 
the clinical database will be locked.  
10.11  Retention of Data  
The study file and all source data sho uld be retained until notification is given by the sponsor 
for destruction.  
If the investigator withdraws from the trial and relinquishes his/her responsibility for the 
maintenance and retention of records, he/she must notify the sponsor in writing so that  
arrangements can be made to properly store the trial materials.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 63 of 69 Global Versio n 2.0 10.12  Publication and Disclosure Policy  
All data and results and all intellectual  property rights in the data and results derived from the 
study will be the property of the sponsor, who may utilize  the data in various ways, such as 
for submission to government regulatory authorities or disclosure to other investigators.  
No publication or disclosure of study results will be permitted except as specified in a 
separate, written agreement between Therac os Sub, LLC and the investigator . If results of 
this study are reported in medical journals or at meetings, all subjects’ identities will remain 
confidential.  
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 64 of 69 Global Versio n 2.0 11 REFERENCE LIST  
IDF (2015). "International Diabetes Federation Diabetes Atlas Seventh Edition."  
Look, A. R. G., R. R. Wing, et al. (2013). "Cardiovascular effects of intensive lifestyle 
intervention in type 2 diabetes." N Engl J Med 369(2): 145 -154. 
Nauck, M. A. (2014). "Update on developments with SGLT2 inhibitors in the management 
of type 2 diabetes. " Drug Design, Development and Therapy 8: 1335 -1380.  
Santer, R., M. Kinner, et al. (2003). "Molecular analysis of the SGLT2 gene in patients with 
renal glucosuria." J Am Soc Nephrol 14(11): 2873 -2882.  
Scheen, A. J. and L. F. Van Gaal (2014). "Combating the  dual burden: therapeutic targeting 
of common pathways in obesity and type 2 diabetes." Lancet Diabetes Endocrinol 2(11): 
911-922. 
Schwartz, S., A. N. Fabricatore, et al. (2012). "Weight reduction in diabetes." Adv Exp Med 
Biol 771: 438 -458. 
Seufert, J. (2 015). "SGLT2 inhibitors - an insulin -independent therapeutic approach for 
treatment of type 2 diabetes: focus on canagliflozin." Diabetes Metab Syndr Obes 8: 543 -
554. 
Van den Heuvel, L. P., K. Assink, et al. (2002). "Autosomal recessive renal glucosuria 
attributable to a mutation in the sodium glucose cotransporter (SGLT2)." Hum Genet 111(6): 
544-547. 
Zhang, W., A. Welihinda, et al. (2011). "EGT1442, a potent and selective SGLT2 inhibitor, 
attenuates blood glucose and HbA(1c) levels in db/db mice and prolon gs the survival of 
stroke -prone rats." Pharmacol Res 63(4): 284 -293. 
 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 65 of 69 Global Versio n 2.0 Appendix 1  Schedule of Events  
Procedure  Screening  Run-in Treatment  Follow -up 
Visit Number  V1/ 
Screening  V2/ 
Run In  V3/ 
Randomization  V4/ 
6 weeks  V5/ 
12 weeks  V6/ 
18 weeks  V7/ End of 
Treatment  V8/ 
Follow up  
Time to Randomization  -3 -1 0 6 12 18 24 26 
Informed Consent  X        
Screening for I/E Criteria  X  X      
Medical History  X        
Diet and Exercise Counseling   X       
Physical Examination    X     X 
Abbreviated Physical Examination  X      X  
Vital Signs  X  X X X X X X 
Measure Weight  X  X X X X X X 
Electrocardiography  X  X    X X 
Clinical Laboratory Tests  X  X X X X X X 
Diary and Glucometer Dispensation   X       
Dispensing Run -in Drug   X       
Diary and Glucometer Record Review    X X X X X X 
Dispensing Investigational Product    X  X    
Adverse Events Assessments   X X X X X X X 
Concomitant Medication Assessments   X X X X X X X 
 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 66 of 69 Global Versio n 2.0 Appendix 2  Schedule of Clinical Laboratory Tests  
Procedure  Screening  Run-in Treatment  Follow -up 
Visit number  V1/ 
Screening  V2/ 
Run In  V3/Randomi -
zation  V4/ 
6 weeks  V5/ 
12 weeks  V6/ 
18 weeks  V7/ End of 
Treatment  V8/ Follow 
up 
Time to Randomization Visit (weeks)  -3 -1 0 6 12 18 24 26 
Hematology  X  X X X X X X 
Serum Chemistry and Electrolytes  X  X X X X X X 
Glycemi c Control  X  X X X X X X 
Serum Lipids  X  X  X  X X 
Urinalysis  X  X X X X X X 
Infectious Disease Testing  X        
Urine Pregnancy Test (WOCBP)  X  X X X X X X 
 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 67 of 69 Global Versio n 2.0 Appendix 3  Examples of SGLT2 Inhibitors  
The following medications are prohibited during the study. Othe r SGLT2 inhibitors that may 
be approved for the treatment of T2DM during the THR -1442 -C-423 study will also be 
prohibited as a concomitant medication in this protocol.  
Generic Name  Trade Name  
canagliflozin  Invokana ™ 
canagliflozin plus metformin  Invokamet ™ 
dapagliflozin  Farxiga ™ or Forxiga ™ 
empagliflozin  Jardiance® 
empagliflozin plus linagliptin  Glyxambi® 
empagliflozin/metformin HCl  Synjardy  
dapagliflozin/metformin HCl 
extended release tablet  Xigduo XR  
 
Apr 18 2017 1:03PM HP LASERJET FAX 
n~x.agltflo~'J~t '1'abl.eN 
rllol<'al l\·iall'rotocot: THrt-1442·C·4Z:< 
·-··~· ·--·-···-~ -···-.. ··~ l1lw:llC('I:< ~u\'1, t,Lc 
06 ArrllZOI? 
•• ----·-·----·--- .. ~ ----"~ ....... _ .. ~·· ________ ,,, -..... ,_ .. y·~ _,______ ,,,, ____ ~ ···----
Appendix4 Sponsl)r Signatums 
Study T.itlt:1~ ,<\ J•htmc 3, R!IJ.t<)"mized, lJoub!o Blind, Actlvc·C<"ll.rol.k•d Study to 
1.-:;yjlluatc tho El'!oN• <Jfll<>:<.agl.l!] dn vor.,,t> SltagiJrn:~l m Subjects 
with Type 2 lli•bote.o M~!Jiu•s Whn llaw frmde<Jttllte Olyoemlc 
Control by Mc:tfiwuti• 
lltudy Nnntb•n 
Vl,l) Fin111 Dntc: lHR· 144~1-lc-42.1 
or, April 2(117 
'l1t!s cJ ittlCii.l ~!udy protuc!ll Willi ~ubjoctto orltlcnl. t~vicw nd hil~ boot.> approv•'<i by tho 
•poii~0-1, Hte fbi lowing par11011Ml L'Oillrlbt.tte.rl l<:• writing a. dl<)r appt"O\'ing lhi~ p!X1I.OMI: 
Signoo:JL~¢- ----·--·-····--Adrbn ll1mc •· 
P~<,tooc>l Orlgiontw: 
1\'f:!~Mch~ Kotl• Ovmm~l U>s~>it!~l 
c:m:~~uJhuU: f~ll' 1'I'bti:J'UC.()S Sub,. LLC 
Slgncd:_r~U1 _____ .=frl:~_ __ 
Robert K 1"~111'~'" M.D. 
Mud!oal MorJlt<>~· 
C<>n~III11U1t lk>l' "lll<::rnc<JO S<tl>, Lt,C 
Co.nfideutlill J) tc: t-( /il /17 
~ -------·-----------·----------' p. 1 
Bexagliflozin Tablets   Theracos Sub, L LC 
Clinical Trial Protocol : THR -1442 -C-423  06 April 2017   
   
 
Confidential  Page 69 of 69 Global Versio n 2.0 Appendix 5  Investigator’s Signature  
Study Title:  A Phase 3, Randomized, Double -Blind, Active -Controlled Study  to 
Evaluate the Effects of Bexagliflozin versus Sitagliptin in Subjects 
with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic 
Control by Metformin  
Study Number:  THR -1442 -C-423 
V2.0  Final Date:  06 April 2017  
I have read the protocol described above. I agree to comply with the International Conference 
on Harmonisation (ICH) Tripartite guideline on Good Clinical Practice (GCP) and all 
applicable regulations and to conduct the study as described in the protocol.  
I agree to ensure that Financial Disclosure Statemen ts will be completed by me and my sub-
investigators  at the start of the study and for up to 1 year after the study is completed, if there 
are changes that affect my financial disclosure status.  
I agree to ensure that the confidential information contained in this document will not be 
used for any purpose other than the evaluation or conduct of the clinical investigation without 
the prior writte n consent of Theracos Sub , LLC.  
 
 
Signed:    Date:    
Clinical Investigator  